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Abstract	
  
Plasmodium falciparum-associated severe malarial anemia [SMA, hemoglobin
(Hb)<5.0g/dL] is a leading cause of morbidity and mortality in African children.
Examination of the host immune response and underlying genotypic traits that condition
SMA can offer an improved understanding of malaria pathogenesis. Previous
investigations have suggested that SMA in high transmission regions is due to, impaired
erythropoiesis hemolysis, and erythrocyte destruction. In the holoendemic transmission
region of western Kenya our studies have shown that dyserythropoiesis drives and
conditions SMA through poorly understood molecular pathways. Pediatric studies have
shown that early erythroid cell populations as well as reticulocyte production is greatly
reduced in children with SMA. The driving force of malaria pathogenesis is multifaceted
and the mechanisms that promote erythropoietic dysfunction are still being understood.
We hypothesize that SMA is conditioned by the immune response through underlying
genetic factors that influence erythropoiesis resulting in a exacerbated disease state. To
that end the studies described in this manuscript focus on the inflammatory chemokines,
monokine induced by gamma (MIG) and interferon gamma-induced protein (IP10) as
well as the hemoglobin-coding gene, hemoglobin alpha 2 (HBA2) in the context of SMA

v

and dyserythropoiesis. The first study described herein, identified MIG and IP10 as
important mediators associated with SMA. In this study we examined circulating MIG
and I10 profiles in non-SMA and SMA children and then genotyped and constructed
haplotypes between 5 individual polymorphic variants within the promoter regions for
the MIG and IP10 for the entire study cohort (n=1,600). The second study described in
this manuscript, utilized a global approach where genome wide association studies as
well as whole-genome transcriptomics identified novel molecular pathways between nonSMA and SMA children. These analyses revealed that the expression of the hemoglobincoding gene, HBA2 is significantly modulated between populations. We then examined
these findings closer and genotyped a larger population for 2 promoter variants with the
same approach described in the first study. Regression analysis of genotype and
haplotype data for both studies revealed significant findings where several variant
haplotypes correlated with SMA outcomes and erythropoietic response. Lastly, we used
an in vitro model of erythropoiesis to determine if recombinant human MIG and IP10 as
well as pediatric study serum (non-SMA and SMA) influence erythroid function. Our
results from these studies revealed that pediatric serum from children with SMA
influenced cell viability as well as erythroid lineage when we examined cell surface
erythroid markers. A similar result was also seen in cell populations that were treated
with the inflammatory mediators, MIG, and IP10 which reflected our proposal that serum
from children with SMA and inflammatory mediators (MIG and IP10) infringe upon
erythroid cell maturation and viability in vivo. Together the results from these studies
independently verify the influence of biomolecular markers and mediators on SMA
outcomes.
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1.0

CHAPTER ONE: INTRODUCTION
1.1

MALARIA PARASITE AND LIFE CYCLE

Malaria is a multifaceted disease that is caused by protozoan Plasmodium
parasites. Plasmodium malaria is a vector borne disease transmitted by female Anopheles
mosquitos.

Currently, there are five human species in the Plasmodium genus: P.

falciparum, P. ovale, P. malariae, P. vivax and the newly emerging zoonotic pathogen P.
knowlesi. The falciparum species account for over 90% of all malaria infections and has
the widest breath of infectious range, where infections have been found on five continents
in the tropics, sub-tropics and temperate zones worldwide (Garcia 2010, Perkins 2011,
Wassmer 2015). P. falciparum also accounts for the highest severity of disease
pathogenesis (mortality and morbidity) where the bulk of transmission occurs in subSaharan Africa. In this region, it is estimated that 250 million infections occur annually
with young children and pregnant women being at the highest risk for severe disease
outcomes. Siaya County in western Kenya, where our study site is located, is
holoendemic for malaria (80% infected from ages 1-4), which further drives high
transmission rates year round (Bloland 1999, WHO 2014)
The life cycle of malaria starts when a parasite carrying female Anopheline
mosquito feeds and transfers sporozoites into the human host. The sporozoites then
migrate to hepatocytes within the liver where they proliferate into haploid merozoites.
After several weeks, merozoites then emerge from the liver and move into the blood
stream where they infect red blood cells (RBCs), undergo asexual replication, and mature
into schizonts. At this stage of the parasitic life cycle, RBCs lyse and thousands of newly
formed merozoites then invade neighboring non-parasitized RBCs. It is also at this stage
1

that the majority of pathology of malaria manifests in the human host. After asexual
replication in RBCs, a portion of merozoites enter sexual replication forming
gametocytes within the blood stream and bone marrow. When the Anopheles mosquitoes
take a blood meal from an infected individual, they also ingest gametocytes. Gametocytes
mature into male and female gametes and reproduce sexually in the mosquito’s midgut to
produce oocysts. The oocysts then divide and burst, yielding thousands of sporozoites
that eventually migrate to the salivary glands of the mosquito, thus starting the
transmission cycle again (Figure 1.1).

1.2

SEVERE MALARIAL ANEMIA AND PATHOGENESIS

P. falciparum infection manifests in a wide spectrum of disease pathogeneses that
ranges from asymptomatic to minor complications such as fever, chills, headaches, and
muscle aches to the more severe: severe anemia, hyperparasitemia, metabolic acidosis,
and cerebral malaria (CM). Severe malaria anemia [SMA, Hemoglobin (Hb) < 5.0g/dL
any parasitemic density] is a hallmark of malarial pathogenesis in sub-Saharan Africa
with the highest burden of disease left to children under the age of five. Several studies
have indicated that SMA in high transmission regions is due to dyserythropoiesis,
impaired erythropoiesis (reduced red blood cell production), hemolysis, and erythrocyte
destruction (Chang 2004, Perkins 2011). In the holoendemic transmission region of
western Kenya, Siaya County, where our group has worked for the past 15 years, we have
shown that ineffective erythropoiesis is a major underlying molecular mechanism that
leads to SMA. Erythrocyte production is also reduced in children that have
contemporaneous hemolytic malaria infections and is mechanistically driven by the
system’s inability to restore lost RBCs and therefore induces a more severe anemic state.
2

Furthermore, in pathology studies where bone marrow has been examined from pediatric
patients with SMA, erythrocyte burst forming (BFU) and colony forming (CFU) units
(Abdalla 2004) are reduced. We have also shown similar results in in vitro models of
erythropoiesis using malaria parasite products and products of the inflammatory response
(Awandare 2010). We have also demonstrated that reticulocyte production is correlated
with the severity of anemia in Kenyan children with malaria (Were 2006). The driving
force of malaria pathogenesis is multifaceted and the mechanisms that promote
erythropoietic dysfunction are still being understood. We and others hypothesize that
anemia during malaria infections is driven primarily by the host immune response and
underlying genetic factors that can exacerbate pathogenesis (Figure 1.1).

1.3

MALARIAL PATHOGENESIS AND THE INNATE IMMUNE
RESPONSE

Malarial pathogenesis primarily manifests during the erythrocytic replication
stage of the parasite cycle where merozoites are rapidly and abundantly released into the
blood stream. It is at this time that infected RBCs, parasites, and parasitic byproducts are
phagocytosed by monocytes, causing hyper-activation of the innate immune response.
Specifically, phagocytosis of the parasitic byproduct P. falciparum hemozoin (PfHz) has
been characterized as an integral component stimulating the innate immune response at
this time. The link between PfHz phagocytosis and SMA pathogenesis remains elusive,
but several ongoing studies are attempting to bridge the gap-in-knowledge for these
mechanisms. However, a variety of regulatory immune genes have been linked to SMA
pathogenesis through erythropoietic suppression (Perkins 2011 and others). Key proinflammatory cytokines such as IL-12, TNF-α and IFN-γ are released early in parasitic
3

infection by activated phagocytes and other regulatory cells. Production of such cytokines
induces inflammation and in response, increased pathogenesis. Also, overproduction of
such mediators has been associated with the severity of P. falciparum infections in
children (Perkins 2000), along with sustained phagocytic cell activation (Biemba 1998).
1.4

MONOKINE INDUCED BY GAMMA (MIG) AND INTERFERON
GAMMA-INDUCED PROTEIN 10 (IP-10) GENETICS AND ROLE
IN PATHOGENESIS

Interferon-gamma-induced monokine (MIG/CXCL9) and IFN-gamma-inducible
protein (IP-10/CXCL10) belong to the IFN-γ chemo-attractant cytokines (chemokines)
that are induced as part of the inflammatory immune response. More specifically, MIG
and IP-10 serve as important mediators in the pro-inflammatory immune response by
induction of their ligand CXCR3 receptor on type-1 helper (Th1) CD4+ T-cells, effector
CD8+ T-cells, and Natural Killer (NK) T-cell innate-type lymphocytes (Blanchet 2012).
Furthermore these chemokines are induced by the pro-inflammatory cytokines IFN-γ and
TNF-α (Gasperini 1999, Wong 1994) and are produced by a host of cells including
neutrophils, monocytes, and endothelial cells (Goebeler 2001, Gasperini 1999, Wong
1994, Farber 1990).
MIG and IP-10 genes can be found amongst several other CXC family
chemokines on chromosome 4 within about 22kb of each other’s coding regions (Figure
1.1). Polymorphic variation of MIG and IP-10 genes have been described by previous
studies of infectious diseases to be associated with a hepatitis B (Xu 2013), HIV/HCV
co-infection (Tenor 2009, 2015), tuberculosis (Tang 2009, Sheikh 2015), Chagas disease
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(Nogueira 2012), Aspergillus fumigatus (Mezger 2008) and

P. falciparum malaria

(Wilson 2013). Several autoimmune and inflammatory diseases such as Graves disease
(Bruck 2010), multiple sclerosis (Galimberti 2007), Crohn’s disease (Lacher 2007), and
type 1 diabetes (Bruck 2009, Klich 2012), as well as cancers (Dimberg 2014, Nakata
2013) have also been linked to MIG and IP-10 polymorphisms.

1.5

HEMOGLOBIN

SUBUNIT

ALPHA

2

(HBA2),

α-THALASSEIMIA GENETICS AND ROLE IN PATHOGENEISIS
The hemoglobin subunit alpha 2 (HBA2) gene codes for one of the two beta
chains that comprise hemoglobin. It is localized within a gene cluster on chromosome 16
of hemoglobin that contains associated genes such as HBA1, HBB, and HBF (Figure
1.2). The coding regions of HBA1 and HBA2 are identical, but vary throughout the 3’
UTR as well as the 5’ UTR. These two alpha chain-coding genes, along with two beta
(HBB) coding genes form the HbA protein and constitute 97% of all hemoglobin. The
remaining portion is primarily composed of fetal hemoglobin (HbF). The pathogenesis
characterized by polymorphic variation of HBA2 are primarily thalassemia-associated
hemoglobinopathies. Deletions and non-deletions of both HBA1 and HBA2 drive the
anemic phenotype of α-thalassemia disease. To date, polymorphic variation in HBA2
alone has not been directly linked to disease pathogenesis apart from the α-thalassemia
hemoglobinopathies. However, α-thalassemia has been studied in the context of malarial
infection by several groups in a number of regions where malaria is prevalent (Evenfold
2008, Fowkes 2008, Williams 2005, Wambua 2006). It hypothesized that carriers of the
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α-thalassemia trait are selectively protected in regions where malaria endemicity is high
(Marteveld 2010).

Figure 1.1 Malarial Anemia: Pathogenesis	
  

The malaria life cycle is biphasic involving the vector (female Anopheles mosquito) and
host (human). The host portion of the life cycle begins when the mosquito takes a blood
meal and inoculates the host with sporozoites. The sporozoites then migrate through the
blood and into the liver where they undergo maturation into the schizont form. Schizont
cells rupture and release merozoites into the periphery thus entering the erythrocytic
portion of the malaria life cycle. It is at this point, that the bulk of human pathogenesis
occurs resulting in anemia caused by parasitic hemolysis, hemorrhage, and
dyserythropoiesis.
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Figure 1.2 MIG and IP-10 Genes

The MIG (CXCL9) and IP-10 (CXCL10) genes are both located on chromosome 4 along
the same region of about 22kb. Each are composed of four exons and separated by three
introns each. The promoter region (~1.5kb from the start codon) for MIG contains several
well-characterized transcription factor-binding sites (TFBS) including STAT3 (Signal
transducer and activator of transcription 3), IRF1 (Interferon regulatory factor 1), and p53
(Tumor protein 53). Similarly, the promoter region for IP-10 contains STAT3 TFBS, as
well as GATA1 (Erythroid transcription factor). Polymorphic variation at two sites (-560560 G/A, -1714 A/T) in the MIG gene promoter and three sites in the IP-10 gene
promoter (-1035 G/A, -1447 A/G, -1919 T/G) are the focus of the studies described in
Chapter 3.

7

Figure 1.3 HBA2 Gene and α-Thalassemia deletion

The HBA2 gene is located amongst other similar hemoglobin coding genes (HBA1 and
HBB) on chromosome 16. These genes have minor differences in their introns and 5’
untranslated regions, but have recognizable distinct features in the 3’ untranslated
regions. The promoter region for HBA2 contains TCF-2 (hepatocyte nuclear factor 2),
cJun, and NF-1 (Nuclear actor 1) sites for transcription factor binding. Polymorphic
variations between two sites (-1789 C/T, -4314 A/G) in the HBA2 gene promoter are the
focus of the studies described in Chapter 4.

8

2.0 CHAPTER TWO: SPECIFIC AIMS
2.1 Specific Aim 1. To determine if the pro-inflammatory chemokines, i.e.,
monokine induced by gamma (MIG/CXCL9) and interferon-γ-induced
protein (IP10/CXCL10), are biomolecular signatures for conditioning SMA.
Hypothesis: Delineation of specific genetic variants within the promoter regions of MIG
and IP10 using high-throughput genotyping will reveal associations with phenotypic
outcomes that influence SMA
These experiments were accomplished by genotyping the Kenyan pediatric cohort
(n=1,600) for several polymorphic alleles located in the promoter regions of the proinflammatory chemokines, MIG and IP10. Genotypic data were used to construct intra(extended) and inter-gene promoter extended haplotypes. Functional association of
extended haplotypes was determined using clinical outcomes. Furthermore, circulating
inflammatory mediator levels (i.e., MIG, IP10, IFN-γ) were evaluated in haplotype
groups associated with SMA using the Cytokine 25-plex Ab Bead Kit, Hu (Invitrogen™).
2.2 Specific Aim 2. To identify novel biomolecular signatures, clustered
genetic variants, and candidate genes associated with SMA using highthroughput genotyping and gene expression arrays.
Hypothesis: Novel biomolecular signatures will emerge from the high-throughput
genome-wide association study (GWAS) and whole transcriptome analysis using the gene
expression array

9

Genetic signatures for SMA were identified from genomic DNA samples from 48
phenotypically characterized children with malarial anemia using a high-throughput
genotyping microarray [Illumina® Human Omni2.5 BeadChip with 2.44 x 106 markers,
(GWAS)] to profile SNPs and copy number variation, and transcriptomics (Illumina®
‘HumanHT-12 v4 Expression BeadChip’, 47,231 probes covering 19,185 gene
transcripts) to measure gene expression. In combination, the GWAS and transcriptomics
provided insight into candidate genes associated with the immune response, signal
transduction, and hematopoiesis in children with malaria. Children with malaria were
stratified into two polarized extremes (non-SMA and SMA) controlling for covariates
that influence anemic outcomes [i.e., age, gender, HIV-1, bacteremia, glucose-6-phospate
dehydrogenase deficiency (G6PD), α-thalassemia, sickle-cell trait (HbS)].
2.3 Specific Aim 3. To determine if the biomolecular markers characterized
in Aim 1 influence erythropoiesis in an in vitro model.
Hypothesis: Chemokine (MIG and IP10) treatment of CD34+ hematopoietic stem cells
will alter an erythroid cell lineage, disrupt cell expansion, and reduce cell viability in our
model for erythropoiesis
The effects of rh (recombinant human) MIG, rhIP-10, rhIFN-γ (Aim1), and
pooled serum from non-SMA and SMA children on erythropoiesis was evaluated using
an in vitro CD34+ hematopoietic stem cell model. Naïve CD34+ cells from US donors
were inducted into the erythroid lineage and treated with biomolecular markers and
pooled serum from disease categories, and their influence on erythropoietic proliferation,
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survival, and differentiation was determined using biochemical, molecular, and flow
cytometric methods.
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3.0

CHAPTER THREE: RESULTS OF SPECIFIC AIM 1

Extended haplotypes in the MIG (CXCL9) and IP-10 (CXCL10) promoters
influence susceptibility to Plasmodium falciparum-associated severe malarial anemia
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ABSTRACT
Plasmodium falciparum-induced severe malarial anemia [SMA, hemoglobin
(Hb)<5.0g/dl] is a leading cause of morbidity and mortality in African children.
However, the underlying genotypic traits that condition SMA have not been fully
elucidated.

Chemokines such as monokine-induced by gamma (MIG/CXCL9) and

interferon gamma-induced protein-10 (IP-10/CXCL10) are typically increased during a
type 1 inflammatory response. We recently observed that circulating levels of MIG and
IP-10 were significantly reduced in children with SMA compared to parasitized children
with non-SMA (P<0.005 and P<0.001, respectively).

To investigate the role of

polymorphic variation in IP-10 and MIG on susceptibility to SMA, extended haplotypes
were constructed using five promoter variants [MIG -1714A/T (rs7670156), MIG 560G/A (rs6532083), IP-10 -1035G/A (rs4257674), IP-10 -1447A/G (rs4508917), and
IP-10 -1919T/G (rs4371639)] on chromosome 4. These particular variants were selected
based on a high minor allelic distribution (>10%) in the population. Binary logistic
regression was performed [controlling for age, gender, nutritional status, co-infections
(HIV-1, bacteremia), G6PD deficiency, α-thalassemia and HbS]. Presence of the IP-101035G/-1447A (GA) haplotype was associated with increased susceptibility to SMA
(OR, 1.62; 95% CI, 1.12-2.35; P<0.01) and inefficient erythropoiesis (RPI<2: OR 1.54;
95% CI 1.01-2.38; P<0.05), while the MIG-560G/-1714A (GA) haplotype was
associated with susceptibility to SMA (OR, 1.73; 95% CI, 1.04-2.88; P<0.05) and an
efficient erythropoietic response (RPI<2 OR, 0.41; 95% CI, 0.22-0.77; P<0.01). Three
extended intragenic haplotypes between the two promoters for each gene were associated
with increased susceptibility to SMA (MIG-560G/IP-10-1447A [GG/GA] OR 1.34; 95%

14

CI 1.00-1.84; P<0.05, OR 1.47; 95% CI 1.00-2.19; P<0.05, and MIG-560G/IP-101035G-1447A [GGG] OR 1.41; 95% CI 1.02-1.96; P<0.05) and inefficient
erythropoiesis (MIG-560G/IP-10-1447A [GG/GA] RPI<2 OR 1.63; 95% CI 1.08-2.45;
P<0.05, OR 1.61; 95% CI 1.00-2.61; P<0.05, and MIG-560G/IP-10-1035G-1447A
[GGG] OR 1.91; 95% CI 1.23-2.96; P<0.01).

In addition, the extended haplotype

[MIG-560G-1714A/IP-10-1035G (GAG)] showed increased susceptibility to SMA (OR
1.58; 95% CI 1.00-2.55; P<0.05) and protection against efficient erythropoiesis (RPI<2:
OR 0.57; 95% CI 0.32-1.00; P<0.05). Carriage of two intragenic extended haplotypes
(MIG-560G/IP-10-1447A[GG] and MIG-560G/IP-10-1035G-1447A [GGG]) showed
significant variability in the production of several inflammatory mediators, including IP10 in children with SMA. Taken together, these data illustrate that variation in MIG and
IP-10 are important in conditioning susceptibility to SMA and erythropoietic responses.
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BACKGROUND
Plasmodium falciparum is responsible for >90% of all malarial infections. Of the
estimated 250 million P. falciparum infections worldwide, 77% of these infections occur
in Africa (WHO, 2014). Children (<5 years of age) in sub-Saharan Africa carry the
highest burden of mortality and morbidity. Even though malarial infection contributes to
several severe clinical manifestations, [e.g., hypoglycemia and cerebral malaria (CM)],
the most common severe disease outcome in children living in holoendemic P.
falciparum transmission areas is severe malarial anemia (SMA: Hb<5.0g/dL as defined
by the WHO, 2000). In holoendemic regions, such as our study site in western Kenya,
malaria-related infant mortality rates are up to 20% (Ongecha, 2006, Perkins 2011).
During malarial intraerythrocytic replication, monocyte/macrophage phagocytosis
of the malarial parasitic byproduct hemozoin (PfHz) occurs, driving immune pathway
dysregulation. Several immune modulatory genes have been identified as key factors that
play roles in erythropoietic suppression and enhanced SMA pathogenesis (Perkins 2011).
The initial host immune response is mediated by production of pro-inflammatory
cytokines such as IL-12, TNF-α and IFN-γ to control parasitic infection. However, this
response also induces enhanced pathogenesis as a result of

monocyte/macrophage

activation. Overproduction of these mediators has also been linked to P. falciparum
infected children (Perkins 2000), as well as sustained phagocytic cell activation (Biemba
1998).
Monokine induced by gamma (MIG/CXCL9) and interferon gamma-induced
protein (IP-10/CXCL10) are chemo-attractant cytokines (chemokines) that are induced as
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part of the inflammatory immune response. More specifically, MIG and IP-10 serve as
important mediators in the pro-inflammatory immune response by induction of their
ligand CXCR3 receptor on type-1 helper (Th1) CD4+ T-cells, effector CD8+ T-cells, and
Natural Killer (NK) T-cell innate-type lymphocytes (Blanchet 2012). Furthermore, these
chemokines are induced by the pro-inflammatory cytokines IFN-γ and TNF-α (Gasperini
1999, Wong 1994) and are produced by a host of cells including neutrophils, monocytes,
and endothelial cells (Goebeler 2001, Gasperini 1999, Wong 1994, Farber 1990).
CXCR3 ligands are influential during inflammatory responses after cerebral injury in
ischemic stroke (Mirabelli-Badenier 2011). In autoimmune diseases such as psoriasis,
MIG is highly expressed (Goebeler 1998). Whereas in thyroid disorders, IP-10 and MIG
activated

through T-cells (Garcia-Lopez 2001) and similarly highly expressed in

multiple sclerosis (Simpson 2000). Furthermore, chronic inflammation that is driven by
the CXC family of cytokines (MIG and IP-10 )has been implicated in ovarian cancer
(Rainczuk 2012).
Previous studies from our group have shown that circulating MIG and IP-10 are
significantly reduced in children with SMA with MIG being predictive of worsening
anemia (Ongecha 2011). Additionally, MIG is down-regulated in experimental malaria
infection in human volunteers (Dunachie 2010). Conversely, both MIG and IP-10 are upregulated in murine models of cerebral malaria (Campanella 2008, Villegas-Mendez
2012) where chemokine expression is isolated primaraliy in the neural regions rather than
in the periphery. Consistent with previous investigations in other diseases, we show that
allelic variation in the MIG and IP-10 genes play an essential role in conditioning
susceptibility to SMA.
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MATERIALS AND METHODS
Study participants. Children < 3 years of age with malaria (n=1,600) were recruited at
Siaya County Hospital in western Kenya, where P. falciparum transmission is
holoendemic (Ongecha, 2006). Study participants were primarily from the Luo ethnic
group, which is the predominant population in this region (>96%). Children with P.
falciparum malaria (any density parasitemia) were categorized into 2 groups: SMA (Hb
level <5.0 g/dL) and non-SMA (Hb level ≥ 5.0 g/dL) according to WHO clinical
guidelines. Children were excluded from the study if they had CM or non–P. falciparum
malaria. In addition, all children were tested for HIV-1 and bacterial co-infections since
these co-infections influence malarial anemia severity (Were 2011, Davenport 2012,
Otieno 2006).

Genetic determinants which influence anemic outcomes, glucose-6-

phosphate dehydrogenase (G6PD) deficiency, α-thalassemia and sickle cell trait, were
also characterized in the cohort. The study was approved by the ethical and scientific
review committees at the Kenya Medical Research Institute (Kenya) and institutional
review board at the University of New Mexico (United States).
Laboratory measures. Venous blood (<3.0 mL) was collected into EDTA vacutainer®
tubes (Becton-Dickinson, NJ, USA) and used to determine complete hematological
measurements (AcT diff2® Coulter, Beckman-Coulter Inc., Fullerton, USA) and
laboratory investigations. Intraerythrocytic cycle asexual stage malaria parasites were
counted against 300 leukocytes using Giemsa-stained blood films. Parasitic counts were
expressed per mL of blood using the patient’s absolute leukocyte count. HIV-1 status
was determined according to our published methods (Otieno 2006). HIV-1 positive
individuals were given trimethoprim-sulfamethoxazole and the appropriate anti-retroviral
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therapies. Bacteremia was determined by microbial cultivation according to our standard
methods (Were 2011). Alpha-thalassemia, sickle cell status and G6PD deficiency were
determined as previously described (Anyona 2011). Intracellular pigment in monocytes
and neutrophils was determined as previously described (Luty 2000, Lyke 2003). The
erythropoietic response was determined by calculating the reticulocyte production index
(RPI) using our previous methods (Were, 2006) and the absolute reticulocyte number
(ARN) was calculated using reticulocyte and erythrocyte counts.
MIG and IP-10 genotyping. Genomic DNA was isolated from buccal swabs (Buccal
Amp™, Epicentre Biotechnologies, Madison WI) and then amplified using GenomiPhi™
V2 DNA Amplification kit (GE Healthcare Life Sciences, Amersham, UK). MIG G560A (rs6532083), A-1713-T (rs7670156), and IP-10 G-1035-A (rs4257674), A-1447-G
(rs4508917), T-1919-G (rs4371639) SNPs were genotyped using the Taqman® 5’-allelic
discrimination Assay-by-design (ABI) on the StepOnePlus™ PCR platform.
Determination of circulating Cytokines, Chemokines, and Effector Molecules. Plasma
samples obtained from venous blood were stored at -70°C until use. Soluble mediator
concentrations were determined using the Human Cytokine Twenty-Five-Plex Antibody
Bead Kit (Invitrogen International), in accordance with the manufacturer’s instructions.
Plates were read on a Luminex 100 system (Luminex) and analyzed using Bio-Plex
Manager software (version IS 2.3; Bio-Rad Laboratories). The detection limits for MIG,
IP-10, and IFN-γ were 4.0 , 5.0 and 5.0 pg/mL, respectively.
Statistical analyses. Statistical analyses were performed using SPSS software (version
19.0), and χ2 and Mann-Whitney U tests were used to examine differences between
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proportions and for pairwise comparisons of medians, respectively. MIG and IP-10
extended haplotypes were constructed using PHASE® software (Stephens Laboratory).
Bivariate logistic regression, controlling for age, sex, HIV-1 status (including both HIV-1
exposure and definitively HIV-1 positive results), bacteremia, and prevalence of sickle
cell trait (HbAS) and α-thalassemia were used to examine associations of genotypes and
extended haplotypes with SMA and RPI (<2). Statistical significance was defined as
P<0.05. Haploview statistical software (Version 4.2) was used to determine SNP and
haplotype distribution and linkage disequilibrium.
Longitudinal follow-up. Upon enrollment (Day 0), parents were asked to bring their
children back to the study clinic every 3 months for the extent of the study (36 months).
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RESULTS
Clinical and demographic characteristics of the study participants (Table 3.1). Study
participants were (<36 months of age) were categorized into aparasitemic (n=300), nonSMA (n=1044; Hb ≥ 5.0 g/dL), and SMA (n=256; Hb<5.0 g/dL). Summaries of clinical
and demographic measures are shown in Table 3.1. Gender ratios across the groups were
normally distributed (P=0.370). The SMA group contained the youngest children
(P<0.001).
As expected based on a priori grouping, hemoglobin (Hb), red blood cell (RBC)
count, and hematocrit were significantly lower in the SMA group (P<0.001). The SMA
group had the highest total white blood cell count (WBC) (P=0.011), as well as a higher
lymphocyte count (P<0.001). Monocyte counts were highest in the non-SMA group
(P<0.001). Mean parasite densities (MPS/µL) and high-density parasitemia (HDP; MPS
≥ 10,000/µL) were significantly lower in the SMA group (P<0.001 and P<0.05,
respectively). The overall reticulocyte production index (RPI) and RPI<2 were lowest in
the SMA group (P<0.001 and P<0.01, respectively). HIV-1 and bacterial co-infections
were comparable between the groups. Glucose 6-phosphate dehydrogenase (G6PD)
deficiency was equally distributed across the groups. Heterozygous sickle cell trait
carriers and α-thalassemia trait carriers were represented the highest in the aparasitemic
group (P<0.001).

Circulating MIG and IP-10 in children with non-SMA and SMA (Figure 3.1).
Circulating chemokines (MIG and IP-10) were examined in the non-SMA (n=215) and
SMA (n=62) groups prior to investigation of MIG and IP-10 promoter variants. Co21

infected (HIV-1 and bacteremia) individuals were removed from the chemokine analysis
because of potential impact on circulating chemokines. MIG and IP-10 levels were
significantly lower in children with SMA compared to the non-SMA group (P<0.005 and
P<0.001 respectively) (Figure 3.1). To determine if these differences were associated
with genetic variation, MIG and IP-10 promoter variants were examined.

MIG and IP-10 genotype distributions (Table 3.2). Genotype frequencies for the two
MIG and three IP-10 promoter variants are stratified according to non-SMA and SMA
(Table 3.2). Distributions of MIG variants were: -560G/A GG (n=943, 0.612), GA
(n=554, 0.360), GG (n=43, 0.028) and -1714A/T GG (n=432, 0.284), AT (n=947, 0.622),
TT (n=144, 0.095). Although both MIG promoter variants were not in Hardy-Weinberg
equilibrium (HWE; χ2=18.52, P<0.0001 and χ2=180.34, P<0.0001, respectively), the
genotypic distribution between the clinical groups (non-SMA and SMA) was not
statistically different for either genotype (P=0.189 and P=0.166).
Distributions of the IP-10 loci were: -1035G/A GG (n=889, 0.596), AG (n=487,
0.327), GG (n=115, 0.077); -1447A/G GG (n=969, 0.620), AG (n=435, (0.278), GG
(n=159, 0.102); -1919G/T GG (n=880, 0.600), TG (n=462, 0.315), TT (n=125, 0.085).
The IP-10 variants showed a departure from HWE (χ2=15.39, P<0.0001; χ2=30.18,
P<0.0001; and χ2=23.96, P<0.0001, respectively).

No differences in genotypic

differences were observed between the non-SMA and SMA groups (P=0.918, P=0.625,
and P=0.869, respectively) (Table 3.2).
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Association of MIG and IP-10 genotypes with susceptibility to SMA (Table 3.3).
Logistic regression modeling, controlling for age, gender, nutritional status, co-infections
(HIV-1, bacteremia), G6PD deficiency, and HbS, was used to examine the association
between the genotypes and susceptibility to SMA. These analyses revealed that carriage
of the homozygous mutant [MIG-1714 TT genotype (n=50)] was associated with
protection against SMA [OR 0.43; 95% CI 0.19-0.98; P=0.04], whereas none of the other
genotypes were significantly associated with susceptibility to SMA.

Association of MIG and IP-10 genotypes with susceptibility to inefficient erythropoiesis
(RPI<2) (Table 3.3).

To determine the association between genotypes and the

erythropoietic response, a standard measure of reticulocyte production that corrects for
anemia and premature release of reticulocytes from the bone marrow, i.e., reticulocyte
production index (RPI<2) was determined. Binary logistic regression was performed as
described above with the outcome variable defined by RPI≥2 (efficient erythropoiesis)
and RPI<2 (inefficient erythropoiesis). These analyses revealed that only one genotype,
i.e., carriage of the heterozygous MIG-560 GA genotype was associated with protection
against inappropriate erythropoiesis [OR 0.60; 95% CI 0.40-0.89; P=0.01].

MIG and IP-10 haplotypic distributions and linkage disequilibrium. Haplotypic
constructs were made to further understand the influence of both intragenic and extended
haplotypes of MIG and IP-10 promoter variants on susceptibility to SMA. From these
analyses, a total of 84 haplotypes (>10% distribution) emerged for intragenic (n=15) and
extended (n=69) haplotypes. To determine if the alleles at different loci were in linkage
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disequilibrium, LD was examined using the Haploview statistical package. Shown in
Figure 3.4 are the D’ values for the five SNPs that were used to create the different
haplotypic constructs.

Association between MIG and IP-10 intragenic and extended haplotypes and SMA
(Table 3.5). Binary logistic regression was performed [controlling for age, gender,
nutritional status, co-infections (HIV-1, bacteremia), G6PD deficiency, and HbS] to
determine the association of the haplotypes with SMA. There were four intragenic
haplotypes associated with increased susceptibility to SMA [OR 1.35-1.73; 95% CI 1.002.88; (P=0.01-0.05)]. None of the intragenic haplotypes were associated with protection
against SMA.
For the extended haplotypes, there were 17 constructs associated with increased
susceptibility to SMA [OR 1.34-2.00; 95% CI (Range) 1.00-3.40; P=0.001-0.05]. In
contrast, four extended haplotypes showed protection against SMA [OR 0.48-0.69; 95%
CI 0.25-1.00; P<0.010-0.05].

Association between MIG and IP-10 extended haplotypes and RPI<2 (Table 3.5). Using
the same binary regression model described above, we performed analyses using the
parameters of RPI≥2 (efficient erythropoiesis) and RPI<2 (inefficient erythropoiesis).
These analyses indicated that carriers of the intragenic IP-10-1035G/-1447A (GA and
GG) haplotypes showed increased inefficient erythropoiesis [OR 1.35-1.62; 95% CI 1.002.35; P< 0.05], whereas carriers of the MIG-560/-1714A (GA) haplotype had protection
against inefficient erythropoiesis [OR 0.41; 95% CI 0.22-0.77; P<0.01].
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Analyses of the extended haplotypes revealed that there were three haplotypes
associated with enhanced inefficient erythropoiesis [OR 1.61-1.91; 95% CI 1.00-2.96;
P=0.001-0.05], while two haplotypes were associated with protection against inefficient
erythropoiesis [OR 0.30-0.38; 95% CI 0.17-0.61; P<0.001].

MIG and IP-10 haplotypes associated with both SMA and erythropoietic responses
(Figure 3.3). A summary of the haplotypic constructs associated with significant
susceptibility to both SMA and RPI<2 are shown in Figure 3.3 Although seven of the
haplotypes showed the same directionality for susceptibility to SMA and an RPI<2, two
of the haplotypes demonstrated increased susceptibility to SMA in the context of
protective response on the RPI.

Functional association between haplotypic variants and circulating inflammatory
mediators (MIG, IP-10, and IFN-γ) (Table 3.6). The functional association between
haplotypes associated with susceptibility to both SMA and erythropoietic responses (n=9)
was investigated by comparing MIG, IP-10, and IFN-γ between carriers and non-carriers
of the haplotypes.

The GG haplotype at the MIG-560G/IP-10-1447A locus was associated with increased
IFN-γ levels [non-GG Median: 11.17, IQR: 26.24; GG Median: 13.15, IQR: 22.94,
(P=0.858)] and a significantly reduction in IP-10 levels [non-GG Median: 240.59,
IQR:606.38; GG Median: 235.74 IQR: 336.76, (P=0.05)] in circulation. Furthermore, the
pro-inflammatory eosinophil cytokine IL-5 ([non-GG Median: 2.11, IQR: 3.70; GG
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Median: 3.00 IQR: 3.51, (P=0.046); ([non-GGG Median: 2.01, IQR: 3.66; GGG Median:
3.40 IQR: 3.54, (P=0.012)] was elevated where as TNF-α [non-GG Median: 24.70, IQR:
51.04; GG Median: 19.90 IQR: 29.40, (P=0.025); non-GGG Median: 24.30, IQR: 48.90;
GGG Median: 18.52 IQR: 29.40, (P=0.017)] was significantly decreased in circulation
for SMA/RPI associated haplotypes. Interestingly, the anti-inflammatory cytokine IL-10
was significantly lower [non-GG Median: 258.77, IQR: 680.14; GG Median: 178.42
IQR: 311.95, (P=0.031); non-GGG Median: 94.51, IQR: 196.80; GGG Median: 71.20
IQR: 225.58, (P<0.001)] for GG and GGG haplotypes.

DISCUSSION
Chemokines serve as chemotactic signaling cytokines, which stimulate cell migration in
response to several types of induction. In the context of infectious disease, chemokines
are produced during the pro-inflammatory immune response and serve as activators of
several types of immune cells (Zlotnik 2012).

Our previous studies reported high

induction of MIP-1α and MIP-1β and suppression of RANTES in children with SMA
(Ochiel 2005, Were 2006). In this study, we report an association of the chemokines,
MIG and IP-10, with SMA and furthermore illustrate how chromosome 4 MIG and IP-10
promoter variation influence erythropoiesis and SMA outcomes. In agreement with our
previous study and that of another, children with severe malaria had low levels of MIG
and IP-10 in circulation (Dunachie 2010 and Ongecha 2011). However, contrary to these
findings, studies conducted using murine models for cerebral malaria (CM) show an upregulation of both MIG and IP-10 (Villegas-Mendez 1990, Campanella 2008).
Furthermore, investigations in India and Ghana have also shown strong association with
fatal P. falciparum human CM and increased IP-10 (Armah 2007, Jain 2008). This
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demonstrates that disease outcomes (SMA vs CM) may be influenced differently by the
initial innate immune response, and where CM phenotypes are the results of central
nervous system influence, SMA is a result of erythropoietic, hemolysis, and red blood
cell dysregulation. Also, these results provide further evidence that phenotypic outcomes
are conditioned based on underlying genetic traits of a population.
There have been several studies that have investigated polymorphic variation for
the CXCR3 ligands (MIG, IP-10) and pathogenesis. A study by Deng et al. showed an
positive association between a IP-10 promoter polymorphism and progression of hepatitis
B virus infection (Deng 2008). Polymorphisms in MIG and IP-10 are also correlated
positively with the intensity of myocarditis in Chagas disease (Nogueira 2012). A
longitudinal study investigating a single IP-10 polymorphism predicted increased
survival in bone-marrow transplant recipients (Nakata 2013).

In the context of

autoimmunity, carriage of particular IP-10 haplotypes is associated with the progression
of multiple sclerosis (Galimberti 2007), and several MIG and IP-10 haplotypes were
shown to be associated with type-1 diabetes in a German population (Bruck 2009). MIG
polymorphisms have also been associated with Crohn’s disease (Lacher 2007).
To date, there have been no investigations focusing on MIG and IP-10 promoter
polymorphic variation and susceptibility to SMA. Using logistic regression modeling,
we demonstrate that two haplotype constructs (MIG-560A/-1714T and IP-10-1447A/1919T) for promoter variants of MIG and IP-10 are significantly associated with
susceptibility to SMA.
against SMA.

Conversely, MIG-560G/-1714T carriers showed protection

Interestingly, examination of seven intragenic extended haplotypes

showed increased susceptibility to SMA, whereas ten extended haplotypes indicated
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protection against SMA. To further understand the impact of the erythropoietic response
on the pathogenesis of SMA in the context of the study, the association between
haplotypic groups that showed association with susceptibility to SMA were also utilized
as a measure for efficient erythropoiesis, RPI, as the outcome variable. These analyses
revealed that presence of the MIG-560G/-1714A (AT) and IP-10-1447A/-1919T (AT)
haplotypes were associated with increased susceptibility to SMA and an elevated risk of
inefficient erythropoiesis. Similarly, six extended intragenic haplotypes between the two
promoters were associated with enhanced susceptibility to and inefficient erythropoiesis.
In contrast, an extended haplotype (MIG-560G IP-10-1447A: GA) showed protection
against both SMA and inefficient erythropoiesis.
Our analysis of the functional association of haplotypic groups with SMA and
erythropoietic response identified several circulating biomolecular mediators in our
population. Through these measures, the pro-inflammatory mediator IFN-γ was reduced
in GG haplotype carriers. In comparison, IP-10 was significantly unregulated in the same
population. However, there is a temporal disconnection between the influence of IFN-γ
and its downstream-mediated chemokine, IP-10.
Concomitantly, these results demonstrate an association of circulating MIG and
IP-10 with SMA. These data further illustrate how several haplotypic groups within the
locus of MIG and IP-10 promoters influence erythropoiesis and SMA, and more
specifically, how extended haplotypes between promoter regions show association with
differential regulation of soluble mediators, including IP-10.

28

COMPETING INTERESTS
None of the authors of the manuscript have a personal or financial competing
interest that influences the interpretation of data or presentation of any information
contained herein.

ACKNOWLEDGMENTS
This work was supported by the National Institute of Health grants RO1 AI51305
(DJP), D43 TW05884 (DJP). We are grateful to the parents, guardians, and children
from the Siaya District community for their participation in the study. We also thank all
the University of New Mexico-KEMRI staff and the Siaya District Hospital staff for their
support during this study. We thank the Director KEMRI for approving this manuscript
for publication.

29

TABLE AND FIGURE LEGENDS
Table 3.1. Clinical and Demographic Characteristics.
Parasitemic children (n=860) were categorized into SMA (Hb<5.0 g/dL’ n=152) and nonSMA (Hb≥ 5.0 g/dL; n=708) according to WHO guidelines. Data are presented as the
median (Interquartile range, IQR) unless stated otherwise. Reticulocyte production index
(RPI) were calculated using previously described methods (reticulocyte index (RI)=
(reticulocyte count × hematocrit)/30.7 (average hematocrit of children <5.0 years of age
in Siaya District); maturation factor (MF)= 1+0.05(30.7-hematocrit); RPI=RI/MF; Were
2009)

a

Chi-Square test was used to determine differences in proportions .

b

Kruskal-

Wallis test was used to determine differences in medians. P<0.05 was considered
significant

Figure 3.1. Circulating chemokine levels in parasitemic children.
Concentrations of chemokines (pg/mL) were measured in plasma from children <3.0
years with P. falciparum malaria using a Human Cytokine 25-plex Antibody Bead Kit
and Luminex® 100™ system (See materials and methods for description).
Concentrations of circulatingIP-10, and MIG (pg/mL) were determined for 277 children
[SMA (n=62) and non-SMA (n=215)].

Box-plots depict the data where the box

represents the interquartile range, the line through represents the median, and whiskers
represent the 10th and 90th percentile. When compared to the non-SMA group, circulating
levels of MIG and IP-10 were significantly reduced in children with SMA relative to
those without SMA (P<0.005 and P<0.001 respectively) Differences between groups
were compared by Mann-Whitney U test.	
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Table 3.2. Association of MIG and IP-10 Genotypes and SMA/RPI.
Binary	
   logistic	
   regression	
   analyses	
   for	
   haplotypes	
   were conducted in SPSS for
parasitemic children controlling for covariates (age, gender, HIV-1, parasite count,
G6PD, bacteremia, α-Thalassemia, and sickle-cell trait). Data presented as percentages
and p-values from x2	
  analysis.	
  

Table 3.3. Association of MIG and IP-10 Haplotypes and SMA/RPI.
Binary logistic regression analyses for haplotypes was conducted in SPSS for parasitemic
children controlling for covariates (age, gender, HIV-1, parasite count, G6PD,
bacteremia, α-Thalassemia, and sickle-cell trait). Indicates significance (P<0.05). Data
are presented as Odds Ratios (95% Confidence Interval).	
  

Figure 3.3 and Table 3.4. Association between MIG/IP-10 extended
haplotypes and SMA (Top) and RPI (Bottom).
The cross-sectional analysis between extended haplotypes and SMA (Hb<5.0g/dL) and
RPI (<2) were determined in parasitemic children (n=860). Binary logistic regression
analysis, controlling for age, gender, the coinfections of HIV-1 and bacteremia, and
genetic variants of G6PD deficiency, Sickle cell, and α-Thalassemia traits were used to
determine odds ratios (ORs,) and 95% confidence intervals (CI). Individuals not carrying
haplotype were used as reference group. Significance for analysis was set at P<0.05. n
values beneath the figure represent the number of individuals with corresponding
haplotype you may need to submit a supplemental table with all the haplotypes that had
over 5% representation in the population.
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Figure 3.4 Linkage disequilibrium between MIG and IP-10 promoter gene
polymorphisms.
Genotypic data for each promoter SNP variant was examined for LD using Haploview
statistical package (see materials and methods). D’ values are given in the intersecting
boxes where the darker red boxes signify a stronger linkage disequilibrium between
alleles. SNP position relative to each gene is indicated (1-5).

Figure 3.5. Circulating biomolecular molecules (25-plex) and Haplotypic
variants.
Concentrations of chemokines (pg/mL) were measured in plasma from children <3.0
years with P. falciparum malaria using a Human Cytokine 25-plex Antibody Bead Kit
and Luminex® 100™ system (See materials and methods for description). Children
(n=184) were categorized into those the GG haplotype (n=88) and non-GG carriers
(n=96) and GGG haplotype (n=78) and non-GGG carriers (n=82). Box-plots depict the
data where the box represents the interquartile range, the line through represents the
median, and whiskers represent the 10th and 90th percentile. Differences between groups
were compared by Mann-Whitney U testa.
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TABLES AND FIGURES
Table 3.1. Clinical and Demographic Characteristics.

Characteristic

Aparasitemic

non-‐SMA	
  

SMA	
  

P-‐value	
  

300	
  

1044	
  

256	
  

N/A

49:51	
  

49:51

53:47	
  

0.370 	
  

11.3	
  (13.3)

12.8	
  (10.5)	
  

10.1	
  (10.5)	
  

<0.001 	
  

	
  	
  	
  Hemoglobin	
  (g/dL)	
  

10.3	
  (2.5)	
  

7.6	
  (2.9)	
  

4.2	
  (1.0)	
  

<0.001 	
  

	
  	
  	
  RBC	
  	
  count,	
  x	
  10 /L	
  

4.6	
  (1.0)	
  

3.5	
  (1.9)

3.4	
  (1.8)

<0.001 	
  

	
  	
  	
  Hematocrit,	
  (%)	
  

32.6	
  (7.3)	
  

23.8	
  (12.2)

22.8	
  (10.8)

<0.001 	
  

	
  	
  	
  WBC	
  count	
  (10 /µL)	
  

11.0 (7.3)

11.7 (6.2)

14.9 (9.8)

<0.05 	
  

	
  	
  	
  Lymphocytes	
  (10 /µL)	
  

43.2	
  (22.1)	
  

48.5	
  (18.9)	
  

55.8	
  (20.9)	
  

<0.001 	
  

7.5	
  (5.4)	
  

8.5	
  (5.8)	
  

7.5	
  (3.9)	
  

<0.001 	
  

Number,	
  n
Gender,	
  %F:M	
  
Age,	
  months	
  

a

b

Hematological	
  Indices	
  
12

3

3

3

	
  	
  	
  Monocytes	
  (10 /µL)	
  
Parasitological	
  Indices	
  

28,675	
  (79,130)	
   22,294	
  (66,103)	
  

b
b
b

b

b
b

b

	
  	
  	
  Parasitemia,	
  MPS/µL	
  

-‐	
  

	
  	
  	
  High-‐density	
  Parasitemia,	
  n	
  (%)

-‐	
  

747	
  (70.5)	
  

168	
  (63.9)	
  

<0.05 	
  

0.60	
  (0.69)

0.70	
  (0.99)	
  

0.57	
  (0.83)	
  

<0.001 	
  

19 (7.7)

140 (13.8)

22 (9.3)

<0.01

	
  	
  	
  HIV-‐1	
  Status,	
  n	
  (%)

12	
  (4.0)	
  

31	
  (3.0)	
  

13	
  (5.2)

0.193 	
  

	
  	
  	
  Bacteremia,	
  n	
  (%)	
  

39	
  (12.7)	
  

98	
  (9.3)	
  

21	
  (8.0)	
  

0.128 	
  

	
  	
  	
  G6PD	
  deficiency,	
  n	
  (%)	
  

10	
  (4.0)	
  

38	
  (4.1)	
  

6	
  (3.0)	
  

0.666 	
  

	
  	
  	
  Sickle	
  cell	
  trait,	
  n	
  (%)	
  

54	
  (17.7)	
  

169	
  (16.2)	
  

18	
  (7.1)	
  

<0.001 	
  

	
  	
  	
  α-‐thalassemia,	
  n	
  (%)	
  

68	
  (26.4)	
  

168	
  (18.7)	
  

45	
  (19.2)	
  

<0.05 	
  

<0.01 	
  
a

Reticulocyte	
  Indices
	
  	
  	
  Reticulocyte	
  Production	
  Index	
  (RPI)	
  
	
  	
  	
  RPI<2.0,	
  n	
  (%)

b

a

Co-‐infections
a
a

Genetic	
  Variants	
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a

a

a

Figure 3.1. Circulating chemokine levels in parasitemic children.
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Table 3.2. MIG and IP-10 genotype distributions

Aparasitemic

non-SMA

SMA

Total

P value

GG, n (%)

161 (57.3)

613 (61.9)

169 (63.1)

943 (61.2)

0.189

GA, n (%)

116 (41.3)

348 (35.1)

90 (33.6)

554 (36.0)

AA, n (%)

4 (1.4)

30 (3.0)

9 (3.4)

43 (2.8)

AA, n (%)

64 (22.7)

290 (29.6)

78 (30.0)

432 (28.4)

AT, n (%)

185 (65.6)

604 (61.6)

158 (60.8)

947 (62.2)

TT, n (%)

33 (11.7)

87 (8.9)

24 (9.2)

144 (9.5)

GG, n (%)

166 (60.4)

569 (59.5)

154 (59.5)

889 (59.6)

AG, n (%)

85 (30.9)

315 (32.9)

87 (33.6)

487 (32.7)

AA, n (%)

24 (8.7)

73 (7.6)

18 (6.9)

115 (7.7)

AA, n (%)

188 (65.7)

618 (61.7)

163 (59.3)

969 (62.0)

AG, n (%)

72 (25.2)

281 (28.0)

82 (29.8)

435 (27.8)

GG, n (%)

26 (9.1)

103 (10.3)

30 (10.9)

159 (10.2)

GG, n (%)

160 (60.6)

564 (59.9)

156 (59.8)

880 (60.0)

TG, n (%)

82 (31.1)

297 (31.5)

83 (31.8)

462 (31.5)

TT, n (%)

22 (8.3)

81 (8.6)

22 (8.4)

125 (8.5)

MIG (G-560A)

MIG (A-1714T)
0.166

IP10 (G-1035A)
0.918

IP10 (A-1447G)
0.625

IP10 (G-1919T)
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0.869

Table 3.3. Association of MIG and IP-10 Genotypes with SMA and RPI<2.

Genotype

SMA
Odds Ratio

95% CI

P value

MIG -560 G>A

RPI
Odds Ratio

95% CI

P value

MIG -560 G>A

GG (n=782)

1.00

-

-

1.00

-

-

GA (n=438)

0.86

0.61-1.22

0.39

0.60

0.40-0.89

0.01

AA (n=39)

0.71

0.26-1.93

0.51

1.72

0.39-7.52

0.47

MIG -1714 A>T

MIG -1714 A>T

AA (n=172)

1.00

-

-

1.00

-

-

AT (n=573)

0.99

0.69-1.43

0.97

0.87

0.56-1.36

0.54

TT (n=50)

0.43

0.19-0.98

0.04

1.09

0.47-2.52

0.84

IP-10 -1035 G>A

IP-10 -1035 G>A

GG (n=488)

1.00

-

-

1.00

-

-

GA (n=240)

0.96

0.67-1.37

0.81

1.42

0.89-2.24

0.14

AA (n=61)

0.65

0.32-1.32

0.23

0.69

0.35-1.37

0.29

IP-10 -1447 A>G

IP-10 -1447 A>G

AA (n=586)

1.00

-

-

1.00

-

-

AG (n=190)

1.20

0.84-1.72

0.32

1.40

0.88-2.25

0.16

GG (n=47)

0.97

0.54-1.72

0.90

1.07

0.54-2.14

0.85

IP-10 -1919 G>T

IP10 -1919 G>T

GG (n=463)

1.00

-

-

1.00

-

-

GT (n=227)

0.79

0.42-1.49

0.48

0.88

0.44-1.79

0.73

TT (n=68)

0.98

0.68-1.40

0.90

1.52

0.94-2.47

0.09
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Figure 3.2. Linkage disequilibrium between MIG and IP-10 promoter gene
polymorphisms.
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Table 3.4. Association of MIG and IP-10 Haplotypes with SMA and RPI<2.

Haplotypes

SMA Odds Ratio

95% CI

P -value RPI Odds Ratio

95% CI

P- value

GA (n=629)

0.876

0.590-1.300

0.510

AA (n=292)

1.137

0.835-1.549

0.416

0.497

0.338-0.731

0.000

1.177

0.892-1.552

0.249

GG (n=221)

0.838

0.603-1.165

0.293

0.973

0.725-1.305

0.854

AG (n=5)

0.977

0.198-4.818

0.977

-

-

0.999

IP10-1035G/-1447A

IP10-1035G/-1919G
GG (n=661)

0.838

0.499-1.408

0.506

0.536

0.345-0.834

0.006

AT (n=268)

1.231

0.908-1.668

0.181

1.262

0.986-1.614

0.065

GT (n=29)

0.938

0.428-2.059

0.874

1.640

0.873-3.084

0.124

AG (n=14)

1.331

0.434-4.080

0.616

6.357

1.970-20.509

0.002

AG (n=607)

0.873

0.599-1.273

0.481

0.582

0.419-0.808

0.001

AT (n=287)

1.341

0.990-1.818

0.058

1.439

1.117-1.854

0.005

GG (n=210)

0.881

0.638-1.215

0.440

1.082

0.822-1.424

0.576

GT (n=10)

0.529

0.166-1.680

0.280

0.902

0.286-2.847

0.861

GA (n=712)

1.191

0.693-2.047

0.526

0.600

0.359-1.002

0.051

GT (n=327)

0.618

0.458-0.833

0.002

0.992

0.772-1.274

0.949

AT (n=299)

1.411

1.039-1.917

0.028

1.506

1.172-1.936

0.001

AA (n=26)

1.619

0.656-3.993

0.296

2.271

1.028-5.013

0.042

GG (n=702)

1.010

0.597-1.710

0.970

0.527

0.321-0.865

0.011

AA (n=243)

1.390

1.008-1.917

0.044

1.379

1.060-1.793

0.017

GA (n=98)

0.660

0.437-0.997

0.048

1.250

0.851-1.836

0.255

AG (n=72)

1.168

0.705-1.935

0.546

1.391

0.909-2.130

0.129

GA (n=674)

0.657

0.422-1.023

0.063

0.641

0.449-0.915

0.014

AA (n=307)

1.336

0.988-1.805

0.060

1.520

1.185-1.950

0.001

GG (n=228)

1.177

0.860-1.611

0.309

0.958

0.733-1.253

0.754

-

-

0.999

1.485

0.558-3.954

0.429

GG(n=666)

0.970

0.572-1.643

0.909

0.540

0.333-0.875

0.012

AT (n=235)

1.512

1.089-2.101

0.014

1.398

1.071-1.826

0.014

GT (n=97)

0.772

0.510-1.168

0.221

1.250

0.854-1.830

0.251

AG (n=62)

1.228

0.711-2.123

0.461

1.330

0.840-2.105

0.224

AA(n=698)

0.934

0.571-1.530

0.787

0.766

0.506-1.159

0.207

TA (n=425)

1.104

0.822-1.483

0.511

1.297

1.019-1.650

0.035

TG (n=203)

0.761

0.552-1.051

0.098

1.141

0.867-1.502

0.347

AG (n=47)

1.874

0.924-3.800

0.082

1.125

0.685-1.850

0.642

AG (n=661)

0.955

0.605-1.509

0.845

0.702

0.471-1.045

0.081

TG (n=331)

0.711

0.528-0.958

0.025

1.087

0.849-1.391

0.507

TA (n= 268)

1.310

0.998-1.852

0.051

1.330

1.029-1.718

0.029

AA (n=66)

1.292

0.749-2.230

0.357

1.242

0.787-1.961

0.352

AG (n=632)

0.973

0.515-1.838

0.933

0.616

0.350-1.084

0.093

TT (n=525)

1.260

0.778-2.041

0.348

0.692

0.459-1.044

0.079

TG (n=313)

1.284

0.840-1.964

0.249

0.915

0.640-1.308

0.625

AT (n=71)

1.542

0.694-3.424

0.287

1.430

0.758-2.698

0.270

IP10-1447A/-1919G

MIG-560G/-1714A

MIG-560G/IP10 -1035G

MIG-560G/IP10 -1447A

AG (n=10)
MIG-560G/IP10 -1919G

MIG-1714A/IP10 -1447A

MIG-1714A/IP10 -1035G

MIG-1714A/IP10 -1919G
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Haplotypes

SMA Odds Ratio

95% CI

P -value RPI Odds Ratio

95% CI

P- value

GAG (n=614)

1.067

0.701-1.622

0.763

GTG (n=61)

0.594

0.366-0.966

0.036

2.458

1.731-3.491

0.000

1.114

0.710-1.747

0.638

GAA (n=628)

0.848

0.569-1.264

ATA (n=285)

1.432

1.035-1.981

0.418

0.645

0.461-0.903

0.011

0.030

1.546

1.198-1.995

GTA (n=181)

0.719

0.001

0.511-1.013

0.059

1.144

0.855-1.531

GTG (n=150)

0.365

0.699

0.489-0.999

0.049

0.865

0.631-1.186

GAG (n=82)

0.368

1.685

1.011-2.808

0.045

1.241

0.847-1.819

0.268

GAG (n=591)

1.263

0.855-1.866

0.240

0.671

0.469-0.959

0.029

GTG (n=290)

0.575

0.422-0.783

0.000

0.988

0.762-1.282

0.929

GGA (n=609)

0.998

0.688-1.449

0.993

0598

0.430-0.832

0.002

AAA (n=240)

1.273

0.925-1.753

0.139

1.457

1.118-1.898

0.005

GGG (n=199)

0.779

0.563-1.079

0.133

0.931

0.703-1.233

0.616

GAA (n=91)

0.656

0.431-0.998

0.049

1.254

0.846-1.858

0.259

GGG (n=659)

0.863

0.632-1.179

0.355

0.641

0.480-0.854

0.002

AAA (n=154)

1.304

0.879-1.933

0.187

1.199

0.850-1.691

0.302

GAG (n=587)

0.827

0.562-1.216

0.333

0.590

0.424-0.821

0.002

AAT (n=122)

1.384

0.919-2.082

0.120

1.397

0.999-1.954

0.051

GGG (n=108)

0.957

0.636-1.442

0.835

1.018

0.715-1.449

0.922

AGA (n=586)

0.997

0.695-1.432

0.989

0.615

0.450-0.840

0.002

TAA (n=263)

1.250

0.910-1.716

0.168

1.369

1.058-1.772

0.017

TGG (n=155)

0.780

0.546-1.116

0.174

0.959

0.709-1.299

0.789

AGG(n=78)

1.126

0.701-1.809

0.623

1.256

0.848-1.859

0.256

AAA (n=65)

1.224

0.708-2.117

0.468

1.329

0.836-2.114

0.229

AGG (n=612)

0.935

0.588-1.489

0.778

0.614

0.410-0.919

0.018

TGG (n=296)

0.684

0.503-0.932

0.016

1.026

0.793-1.326

0.847

TAT (n=124)

1.099

0.727-1.661

0.653

1.174

0.829-1.664

0.366

AAG (n=569)

0.991

0.686-1.431

0.962

0.570

0.413-0.786

0.001

TAT (n=117)

1.198

0.794-1.807

0.389

1.366

0.972-1.922

0.073

TGG (n=97)

0.887

0.578-1.361

0.583

1.100

0.763-1.586

0.609

TAG (n=85)

0.758

0.487-1.179

0.220

0.997

0.676-1.471

0.988

GAG (n=589)

0.922

0.533-1.597

0.773

0.597

0.370-0.962

0.034

AAT (n=263)

1.193

0.769-1.849

0.431

1.317

0.912-1.902

0.142

GGG (n=196)

0.819

0.515-1.304

0.401

1.016

0.681-1.515

0.939

MIG-560G/-1714A/IP10-1035G

MIG-560G/-1714A/IP10-1447A

MIG-560G/-1714A/IP10-1919G

MIG-560G/-IP10-1035G-1447G

MIG-560G/-IP10-1035G-1919G

MIG-560G/-IP10-1447A-1919G

MIG-1714A/-IP10-1035G-1447G

MIG-1714A/-IP10-1035G-1919G

MIG-1714A/-IP10-1447A-1919G

IP10-1035G/-1447A/-1919G
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Haplotypes

SMA Odds Ratio

95% CI

P -value RPI Odds Ratio

95% CI

P- value

GAGA (n=567)

1.000

0.695-1.438

0.999

ATAA (n=227)

1.401

1.002-1.960

0.049

0.620

0.453-0.849

0.003

1.427

1.089-1.868

GTGG (n=147)

0.707

0.491-1.016

0.010

0.061

0.834

0.609-1.141

GTGA (n=142)

0.817

0.256

0.560-1.190

0.292

1.101

0.804-1.506

0.549

1.297

0.871-1.932

0.201

0.747

0.531-1.051

0.094

GAAG (n=545)

1.106

0.740-1.655

0.623

1.052

0.753-1.469

0.765

ATAT (n=218)

1.388

0.971-1.983

0.072

0.683

0.483-0.842

0.001

GTGG (n=144)

0.781

0.543-1.123

0.183

0.906

0.658-1.246

0.543

GTAG (n=124)

0.379

0.267-0.538

0.000

1.752

1.239-2.478

0.002

GGAG (n=571)

0.818

0.548-1.221

0.325

0.0706

0.510-0.978

0.036

GGGG (n=67)

1.211

0.712-2.059

0.479

0.932

0.605-1.438

0.751

AGAG (n=555)

0.982

0.674-1.431

0.927

0.603

0.453-0.834

0.002

TAAT (n=241)

1.205

0.872-1.665

0.259

1.352

1.035-1.765

0.027

TGAG (n=159)

0.700

0.492-0.995

0.047

1.048

0.774-1.418

0.764

TGGG (n=146)

0.792

0.548-1.145

0.215

0.951

0.696-1.299

0.751

GAGGA (n=322)

1.027

0.760-1.388

0.862

0.737

0.578-0.941

0.014

AATAT (n=107)

1.181

0.772-1.807

0.444

1.417

1.009-1.990

0.044

GGGT (n=74)

0.835

0.509-1.369

0.475

0.909

0.605-1.366

0.645

GAGGT (n=67)

0.828

0.519-1.320

0.427

0.796

0.537-1.179

0.255

MIG-560G/-1714A/IP10-1035G/1447A

MIG-560G/-1714A/IP10-1035G/1447A
GAGG (n=575)
MIG-560G/-1714A/IP10-1447A/1919G

MIG-560G/IP10-1035G/1447A/1919G

MIG-1714A/IP10-1035G/1447A/1919G

MIG-560G/-1714A/IP10-1035G/1447A/1919G
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Figure 3.3. Association between MIG/IP-10 extended haplotypes and SMA
(Top) and RPI (Bottom). 	
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Table 3.5. Circulating inflammatory mediators (25-plex) and haplotypic
variants.
IP-10

Circulating Mediator (pg/mL)

MIG

IFN-γ

Median

IQR

P-Value

Median

IQR

P-Value

Median

IQR

P-Value

GA (n=52)

224.5

626.9

0.629

161.2

310.7

0.832

11.7

28.1

0.52

non-GA (n=176)

253.8

294.2

187

166.7

18.2

28.5

GA (n=54)

215.5

280.9

155.9

178.4

11.7

35.5

non-GA (n=144)

263.6

466.5

193.8

182.3

16.3

21.5

GG (n=66)

282.4

292.5

203.1

182.8

22.9

29.4

203

274.9

152.2

154.7

18.2

20.3

AG (n=30)

241.4

304.5

161.2

201.9

13.4

24.63

non-AG (n=168)

216.4

302.7

158.4

178.6

14.8

31.4

208.7

286.7

159.8

182.2

13.8

29.6

265

422.04

194.3

184.4

16.7

25.7

GG (n=71)

274.9

322.9

153.6

159.4

19.6

27.7

non-GG (n=130)

199.2

259.6

210

187.5

8.55

21.4

GAG (n=146)

231.6

285.03

14.5

31.04

non-GAG (n=42)

183.9

537.4

15.3

22.2

240

302.3

12.3

22.5

224.8

313.8

14.8

28.2

GGG (n=47)

274.9

270.2

24.31

27.16

non-GGG (n=118)

205.4

298.13

20.12

21.6

Intragenic Haplotypes
MIG-560G/-1714A

IP10-1035G/-1447A

non-GG (n=132)

0.384

0.028

0.717

0.050

0.955

0.852

Extended Haplotypes
MIG-560G/IP10 -1035G
0.998

0.773

0.561

MIG-560G/IP10 -1447A
GA (n=43)
non-GA (n=158)

0.081

0.005

0.9

0.068

0.564

0.005

MIG-560G/-1714A/IP10-1035G

ATG (n=21)
non-ATG (n=141)

0.78

0.88

162.9

169.4

155.9

153.75

127.01

161.5

165.8

175.2

196.1

171.97

152.3

153.2

0.76

0.69

0.52

0.6

MIG-560G/IP10-1035G-1447A
0.024
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0.050

0.085
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ABSTRACT
Plasmodium falciparum-induced severe malarial anemia [SMA, hemoglobin (Hb)<5.0
g/dL] is a leading cause of morbidity and mortality in African children. However, the
underlying genotypic traits that condition SMA have not been fully elucidated. Recent
studies in our laboratory from high-throughput genotyping and transcriptomics revealed
that >2 copies of hemoglobin-α 2 (HBA2) and 1.81-fold increase in gene expression,
respectively, were significantly associated with enhanced susceptibility to SMA in a
stratified cohort of Kenyan children (3-36mos.) with polarized clinical phenotypes: SMA
(n=70) and non-SMA (n=74). These signals were validated using in silico analysis for
HBA2, and identified two single nucleotide polymorphisms (SNPs), -1789C/T and 4314A/G, which were then genotyped in the larger cohort (n=1,314). The deletion for α3.7thalassemia was also determined for the population. Promoter genotypes and -α3.7
thalassemia deletions were used in the construction of haplotypes, followed by binary
logistic regression analysis, controlling for covariates (age, gender, G6PD, HIV-1,
bacteremia, and HbAS status). This model revealed that carriage of the HBA2 TT
genotype protected against SMA (OR: 0.60, 95%CI: 0.37-0.966, P<0.05). In addition,
several haplotypic constructs between the promoter variants and α-thalassemia showed
significantly altered susceptibility to SMA and reduced erythropoietic responses (RPI<2)
. In contrast, several haplotypes were significantly associated with protection against
SMA. Taken together, these results demonstrate that variation in the HBA2 promoter, and
HBA2/-α3.7-thalassemia haplotypes are associated with susceptibility to both SMA and
altered erythropoietic responses.
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BACKGROUND
Between 124-283 (198) million cases of malaria with an estimated 367,000755,000 (584,000) malaria-associated deaths occur each year worldwide [WHO 2013].
Plasmodium falciparum malarial infections in sub-Saharan Africa account for
approximately 82% of all malarial infections globally. Furthermore, children under the
age of five and pregnant women carry the highest burden of disease. This burden is
particularly prominent in holoendemic areas of P. falciparum such as our study site in
western Kenya where severe disease primarily manifests as severe malarial anemia [SMA
(any parasitemia and Hb<5.0 g/dL)] (Perkins 2011, Novelli 2010, Ongecha 2006, Bloland
1999, Obonyo 2007, Zucker 1997).
Thalassemias are among the most prevalent hemoglobinopathies induced by a
defect in the synthesis of either α or β globin chain (Higgs 2008 Cohen 2004). Reduction
in the production of either (or both) globin chains results in anemia caused by abnormal
hemoglobin synthesis. The thalassemia disease state is characterized by hemolysis that is
caused by imbalanced and mismatched globin chains, resulting in weak linkage between
clusters (Higgs 1989)Alpha (α) thalassemia is an inherited disorder caused by deletions
and/or mutations between the two α-globin coding genes, HBA1 and HBA2. Variation in
these genes can result in abnormal hemoglobin syntheses, often leading to mild to severe
anemia (Yap 2013 Harteveld 2010). Ordinarily, hemoglobin molecules contain four αglobin genes at two per haploid genome (αα/αα). When both α globin genes are
suppressed, the resultant genotype is heterozygous (--/αα), whereas one α globin gene
inactivation results in heterozygous (-α/αα) (Higgs DR 1989). Mild to severe α-globin
chain defects are caused by the inactivation of any or all of the four α-globin genes,
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further inducing the severe anemia phenotype depending on the relative number of genes
inactivated. Previous studies suggest that homo- and heterozygous thalassemia carriers
are protected from P. falciparum infection (Williams 2005, Wambua 2006, May 2007 ,
Allen 1997, Mockenhaupt 2004, Fowkes 2008).
The most common α-thalassemias are -α3.7 and -α4.2 characterized by 3.7kb and
4.2kb deletions, respectively. Worldwide, there is a distribution of the heterozygous (α3.7/αα) and homozygous (-α3.7/-α3.7) α-thalassemia. However prevalence for the -α3.7
deletion is found in African and Mediterranean populations where the -α4.2 is found
primarily in Asian and Mediterranean populations (Friedman S 1974, Kattamis AC 1996,
Pirastu M, 1982). As such, this study will focus on the -3.7kb (α/-α 3.7) deletion. During
meiosis, the -α3.7 deletion occurs as a result of a reciprocal crossover and misalignment of
homologous block (Z-blocks) overlapping parts of the HBA1 and HBA2 genes on
chromosome 16. This results in the thalassemia phenotype, with heterozygous (-α3.7/αα)
and homozygous (-α3.7/- α3.7) individuals. The -3.7kb deletion removes the promoter
region of hemoglobin subunit alpha 1 (HBA1), and a portion of the coding region itself
leaving the promoter for the hemoglobin subunit alpha 2 (HBA2) largely intact. HBA2
codes for one of the two α-chains of hemoglobin clustered with related genes (e.g., HBA1
and HBB).
In a concurrent study (unpublished), high-throughput genotyping [Illumina®
Human Omni2.5-8v1 BeadChip’ (>2.45x106 markers)] and global gene expression arrays
[HumanHT-12 v4 BeadChip (47,231 probes)] were utilized to identify genetic variants
associated with malaria clinical outcomes in a stratified subset of Kenyan children (336mos.) with SMA (n=70) and non-SMA (n=74). The genotyping studies revealed that
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>2 copies of HBA2, and several polymorphic variants in the promoter region of the gene
were significantly associated with enhanced susceptibility to SMA. In addition, global
gene expression profiling showed a 1.81-fold increase for HBA2 in the SMA group. To
extend and validate the whole genome findings, we performed in silico analysis for HBA2
and identified two (potentially) functional SNPs (-1789C/T, rs2974771 and -4314A/G,
rs1203833) that were then genotyped in a larger cohort of children with malaria
(n=1,314). The current study investigates the influence of HBA2 promoter
polymorphisms and α-thalassemia variation on susceptibility to SMA and inefficient
erythropoiesis characterized by a reticulocyte production index (RPI)<2 in children with
falciparum malaria.
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METHODS
Study participants. Children aged 3-36 mos. (n=1,314) presenting with P. falciparum
malaria at Siaya County Hospital (SCH) were recruited for the study. Children with nonfalciparum malaria species, cerebral malaria, or previous hospitalization (for any reason)
were excluded from the study. Upon enrollment, heel/finger-prick of <100µL blood was
taken to evaluate Hb and parasitemia status. Parasitemic children were stratified into
SMA (Hb<5.0 g/dL, any density parasitemia) and non-SMA (Hb≥5.0 g/dL, any density
parasitemia).
Sample collection. Venous blood (1-3 mL) was obtained from each study participant.
Hematological measures, including a complete blood count (CBC) and reticulocyte
count, along with HIV-1 status and bacteremia status were determined. A portion of the
venipuncture blood was centrifuged and isolated plasma was stored at -80oC until use.
For DNA isolation, buccal cells were collected using MasterAmpTM buccal swab kits
(Epicenter Biotechnologies, USA).
Laboratory evaluation. For determination of parasitemia, thin and thick blood smears
were prepared, stained with Giemsa reagent and examined under oil immersion.
Trophozoites were counted against 300 leukocytes and parasite densities estimated using
the WBC counts from the CBC.
High-throughput genotyping: whole genome genotyping. Genomic DNA was isolated
from buccal swabs using the MasterAmpTM Buccal swab DNA extraction kit (Epicentre
Biotechnologies, Madison, WI), cleaned and concentrated using the genomic DNA kit
(Zymo Research, CA, USA. Parasitemic children (non-SMA and SMA) that were
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selected for this study were age and gender matched in equal proportions (n=48).
Children that were aparasitemic, HIV-1 and/or bacteremia-infected, sickle-cell disease
(SSD) positive, and glucose-6-phosphatase dehydrogenase (G6PD) deficient were
excluded from these analysis. Children were categorized into low Hb levels (SMA cases;
Hb<5.0g/dL; n=22, avg. Hb=4.1) and high Hb levels (non-SMA, controls, Hb= 8.010.9g/dL; n=26, avg. Hb=10.8)]. Genomic DNA sample quality was assessed using the
Agilent 2100 bioanalyzer (Agilent Technologies, CA, USA). Quantitative analysis of
genomic DNA was measured using the Qubit®2.0 fluorimeter and also with the dsDNA
BR assay kit (Invitrogen®). Concentrated DNA (50 ng) was used for the Illumina®
Infinium® HD Super Assay in conjunction with Illumina’s® Human Omni2.5-8v1
BeadChip (Illumina,CA, USA) which is coated with >2.45M markers to profile single
nucleotide polymorphisms (SNPs). The array was scanned on the Illumina® ‘iScanSQ’
platform and the genotype calls were made using Illumina’s® GenomeStudio® genotyping
module. For quality control, those samples with call rates of less than 95% and MAFs
less than 5% were excluded from the analysis. GWAS data analyses were performed
using a ‘full model of regression’ controlling for covariates with ‘SNP and Variation
Suite (SVS) 7.7’ (Golden Helix, Inc, MT, USA).
Gene expression array (transcriptome analysis). Seventy two additional subjects from
the overall pediatric cohort (n=1,654) were chosen using the same selection criteria of Hb
levels: SMA (cases, n=21, avg. Hb=5.13) and non-SMA (controls, n=51, avg. Hb=9.43).
White blood cell (WBC) pellets were used to extract total RNA with the GITC organic
method (Chomczynski 1987; Keller 2004). Total RNA was quantitatively measured
using the Qubit®2.0 fluorimeter and also with the RNA BR assay kit (Invitrogen®).
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Global gene expression profiling was conducted on

the Illumina® HumanHT-12

v4 beadchip array (Illumina,CA, USA) covering >47,000 where transcripts were read on
the Illumina® “iScanSQ” platform. The Illumina GenomeStudio® was used to eliminate
internal assay background noise this yeildinge 60 samples with 19,185 transcripts
expressed overall. Data were further filtered using step-wise procedures to remove
transcripts that were identified as having an “absent” expression/flag quality control step.
Genes that were differentially expressed between two clinical category groups (>1.5 fold
change) and statistically significant between populations were selected for validation.
Correlation tests for gene expression data were conducted using the GraphPad Prism 5®
(GraphPad Software Inc. La Jolla, CA) software. Microarray gene expression data were
processed and examined using GeneSpring GX v13 software (Agilent, CA USA).
HBA2 -1789C/T and -4314A/G, and α-thalassemia genotypes and haplotypes. DNA
was extracted using BuccalAmpTM DNA extraction kits. Genotyping of HBA2 -1789C/T
(rs2974771) and HBA2 -4314A/G (rs1203833) was carried out using Taqman® 5’ allelic
discrimination Assay-By-DesignSM methods according to manufacturer’s protocol
(Applied Biosystems, Inc.). The α- thalassemia -α3.7 deletion was determined using
nested PCR. Primers used for nested PCR were; Forward :5’-AAG TCC ACC CCT
TCC TTC CTC ACC-3’, Reverse 1: 5’-ATG AGA GAA ATG TTC TGG CAC CTG
CAC TTG 3’, and Reverse 2: 5’- TCC ATC CCC TCC TCC CGC CCC TGC CTT TTC
3’. The PCR reaction was performed in a 20 µL reaction mixture containing 100 ng
genomified DNA, 50mmol MgSO4, 10 mmol dNTPs, 12.5 ng and 5 units/µL of
PlatinumTaq DNA polymerase (Promega, Madison, WI) in buffer per manufactures
instructions. Nested PCR conditions were an initial 2 minute denaturation at 94°C,
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followed by 44 cycles of denaturation at 94 °C for 30 seconds, annealing at 65 °C for 1
minute and extension at 72 °C for 2 minutes followed by a final extension at 72 °C for 5
min. PCR products were separated on 3% high resolution agarose gel (Peqlab, Germany)
containing ethidium bromide and visualized under UV illumination. Haplotypes were
constructed using PHASE software (version 2.1).
Statistical Analyses. Comparisons of non-parametric data were determined by ChiSquare test and Mann-Whitney U test, respectively.

The association between the

haplotypes and SMA were examined by binary logistic regression, controlling for
confounders of age, gender, HIV status, bacteremia, sickle cell trait (HbAS), and G6PD
deficiency status. Statistical significance was set at P≤0.05.
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RESULTS
The influence α-thalassemia (-α3.7) deletion and variation in the promoter region
of the HBA2 gene was investigated by stratifying parasitemic children into two clinical
categories: non-SMA (Hb≥5.0 g/dL, n = 1,053) and SMA (Hb< 5.0 g/dL, n = 261).
Demographic, laboratory, and clinical measures for the study participants are summarized
in Table 4.1. Children with SMA were younger (P<0.001) and had lower admission
temperature (°C, P< 0.05). Consistent with a priori grouping, hemoglobin (Hb; g/dL),
red blood cell count, and hematocrit were lower in children with SMA (P<0.001).
Children with SMA had elevated white blood cell counts, along with marked
leukocytosis and monocytosis (P<0.001). Peripheral malaria parasite density (MPS/µL)
and high-density parasitemia (HDP; >10,000/µL) were highest in the non-SMA group
(P=0.003 and P=0.030, respectively). The absolute reticulocyte number (ARN) and
reticulocyte production index (RPI) were higher in the SMA group (P=0.007 and
P<0.001, respectively).

The percentage of children with inefficient erythropoiesis

(RPI<2) was highest in children with SMA (P=0.024). The impact of genetic variants on
the development of SMA was also examined. Sickle cell trait and α-thalassemia deletion
carriers were higher in the non-SMA group (16.4% vs. 8.9%; P=0.025 and 22.5% vs.
19.2%; P<0.001, respectively). HIV-1 co-infection was higher in children with SMA
(5.2% vs. 3.9%; P<0.001), whereas bacteremia was similar between the two groups
(8.1% vs. 9.3%; P=0.225).

Distribution of HBA2 genotypes and α-thalassemia -3.7kb deletion in children with
malarial anemia (Table 4.2). Prevalence of the HBA2-1789C/T (rs2974771) genotype in
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parasitemic children was 43.9% CC, 38.7% CT and 17.4% TT with overall allele
frequencies of C = 0.62 and T = 0.38, respectively. The combined distribution of the
HBA2-1789C/T genotypes displayed significant departure from Hardy-Weinberg
Equilibrium (HWE, c2=2.88, P=0.010). However, the overall genotypic distribution for
the HBA2-1789C/T allele between non-SMA and SMA groups was not statistically
significant (P=0.122).

The HBA2-4314A/G (rs1203833) genotype in parasitemic

children was 55.1% AA, 34.2% AG and 10.8% GG with overall allele frequencies of
A=0.69 and G=0.31, respectively. The distribution of the HBA2-4314A/G genotypes did
not depart from Hardy-Weinberg Equilibrium (HWE, c2=2.46, P = 0.117). Likewise,
genotypic distribution for the HBA2-4314A/G allele between non-SMA and SMA groups
was not statistically significant (P=0.774). The α-thalassemia deletion was distributed as
42.3% for αα/αα, 38.9% for -α/αα and 18.8% -α/-α respectively. The distribution of the
HBA2-4314A/G genotypes did not depart from Hardy-Weinberg Equilibrium (HWE, c2
= 3.11, P = 0.083) and were normally distributed between clinical categories (P = 0.234).

Distribution of HBA2 promoter and α-Thalassemia -3.7kb deletion haplotypes in
children with severe malarial anemia (Table 4.3). Haplotype constructs for the two
HBA2 polymorphisms displayed the overall frequencies of: 0.58 for -1789C/-4134A
(CA), 0.18 for TG, 0.15 for TA, and 0.09 for CG. Haplotype distribution for children
with SMA (n= 261) was 0.51 for CA, 0.15 TG, 0.24 for TA, and 0.10 CG. This
distribution frequency was not significantly different for haplotype carriers (non-CA
versus CA, P = 0.66; non-TG versus TG, P = 0.28; and non-CG versus CG, P = 0.65)
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when compared between non-SMA and SMA groups. However, TA haplotype carriers
were significantly less represented in children with SMA (P = 0.01).
Haplotypes between both HBA2 polymorphisms and the α-Thalassemia -3.7kb deletion
were also constructed. Haplotypes were distributed for the -1789C/T and -3.7kb αα/αα
combination at: 0.36 -1789 for C/α, 0.30 for C/-α, 0.25 for T/α, and 0.08 for T/-α
amongst parasitemic children. When compared between non-SMA and SMA children,
frequencies for these haplotypes were not significantly different for 0.23 -1789C/α and
0.23 for C/-α, and 0.21 for T/α. Conversely, T/-α haplotypes were significantly lower in
SMA children (0.18; P = 0.05). In parasitemic children, -4134A/G and -3.7kb αα/αα
haplotypic combination showed frequency of 0.49 for A/α, 0.24 for A/-α, 0.13 for G/α,
and 0.14 G/-α. When categorized into non-SMA and SMA children, these 0.22 for A/α,
0.22 for A/-α, 0.23 for G/α, and 0.24 G/-α, haplotypes were not significantly distributed
between groups. Both polymorphisms were combined with the α-Thalassemia -3.7kb
deletion to create for CA/α (0.33) CA/-α (0.26), CG/α (0.03), CG/-α (0.04), TA/α (0.12),
TA/-α (0.03), TG/α (0.14), and TG/-α (0.05) distributions. These haplotypes were then
categorized into non-SMA and SMA and showed the following CA/α (0.49), CA/-α
(0.27), CG/α (0.04), CG/-α (0.05), TA/α (0.11), TA/-α (0.01), TG/α (0.12), and TG/-α
(0.06) distributions.
Association of HBA2 genotypes and α-thalassemia deletion variants with
parasitemia, SMA, and RPI (Table 4.4). Logistic regression analysis was performed to
investigate the association of HBA2 -1789C/T (rs2974771), HBA2 -4314A/G
(rs1203833), and α-thalassemia -3.7kb deletion with parasitemia, SMA, and RPI .
Covariates that could influence the different clinical outcomes such as age, sex, parasite
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count, co-infections (bacteremia and HIV-1), and genetic variables (sickle-cell trait and
glucose-6 deficiency) were controlled for in the regression model. There was no
significant association between HBA2 -1789 genotypes and either parasitemia or RPI<2.
However, carriers of the wild-type (TT) were significantly less likely to develop SMA
(41%, OR=0.59 [95%CI, 0.37-0.97], P=0.04).
Carriers of the HBA2 -4314 AG genotype had a 38% increase in the risk of
developing parasitemia (OR=1.38 [95%CI, 0.99-1.92], P=0.05). However, none of the
HBA2 -4314 genotypes were associated with susceptibility to SMA or inefficient
erythropoiesis.
Interestingly, none of the α-thalassemia -3.7kb deletion variants were associated
with susceptibility to SMA or inefficient erythropoiesis. There was, however, a nonsignificant 30% protective advantage against parasitemia for homozygous carriers of the
α-thalassemia -3.7kb deletion (-α/-α) (OR=0.70 [95%CI, 0.48-1.03], P=0.07).

Association between HBA2 and α-thalassemia -3.7kb deletion haplotypes and SMA
(Table 4.5).

After determining the association between genotypes and the various

clinical outcomes, the influence of haplotypic variance on SMA and RPI<2 was
investigated. Logistic regression modeling of HBA2 and α-thalassemia -3.7kb deletion
haplotypes, controlling for covariates, was performed as described above. Carriers of the
HBA2-1789C/HBA2-4134A (CG) haplotype had a 67% increase in susceptibility to SMA
(OR=1.67 [95%CI, 1.21-2.30], P<0.01), and a 115% enhanced susceptibility to
inefficient erythropoiesis (OR=2.15 [95%CI, 1.26-3.67], P<0.01). In contrast, carriers of
the HBA2-1789C/HBA2-4134A (TA) haplotype showed a 38% protection against the
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development of SMA (OR=0.62 [95%CI, 0.46-0.82], P<0.001), and no significant
association with altered erythropoietic responses (OR=1.28 [95%CI, 0.91-1.79], P=0.16).
The influence of haplotypic constructs between the two individual HBA2 SNPs
and the α-thalassemia -3.7kb deletions was then examined. When the HBA2-1789C
allele was examined within the context of the α-thalassemia -3.7kb deletions, C/-α
carriers showed a 3-fold increased susceptibility to SMA (OR=3.23 [95%CI, 1.64-6.37],
P<0.01). In contrast, carriers of the HBA2-1789T allele and a -3.7kb deletion (T/-α) had a
71% reduction in susceptibility to SMA (OR=0.29 [95%CI, 0.18-0.48], P<0.01). None
of the haplotypic combinations between the HBA2-1789 alleles and -3.7kb deletions had
significantly altered susceptibility to altered erythropoiesis.

Moreover, none of the

haplotypic constructs for HBA2-4134 alleles and α-thalassemia -3.7kb deletions showed
any significant changes in susceptibility to either SMA or erytropoietic outcomes.
After completion of these analyses, full haplotypic constructs between both HBA2
combinations and α-thalassemia -3.7kb deletions were investigated.

These analyses

revealed that carriers of the CG alleles with and without -3.7kb deletions were 83% and
81% more likely to develop SMA (OR=1.83 [95%CI, 1.01-3.31], P=0.04; and OR=1.81
[95%CI, 1.79-2.77], P<0.01, respectively). In contrast, TA carriers with and without 3.7kb deletions showed 27% and 68% reduced risk of developing SMA (OR=0.73
[95%CI, 0.53-0.99], P=0.04; and OR=0.32 [95%CI, 0.16-0.63], P<0.01, respectively).
There was also a 41% reduction in susceptibility to SMA in carriers of the TG alleles in
the context of a -3.7kb deletion (TG/-α) that was of borderline significance (OR=0.59
[95%CI, 0.35-1.00], P=0.05). Of all of the full constructs examined, only CG/-α carriers
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had altered susceptibility to erythropoietic responses (OR=1.84 [95%CI, 1.02-3.65,
P=0.04).
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DISCUSSION
The pathways that connect genetic variants to phenotypic disease outcomes are
often complicated and poorly understood. In this study, we further the results from a
previous study followed by the candidate gene approach, which has been successful in
characterizing determinants of SMA (Ouma 2008, Ouma 2010, Awandare 2009, Ongecha
2011, Anoya 2011, Kempaiah 2012, Okenyo 2013). This method for discovery, aids in
the development of information for mechanisms and pathways that influence progression
of children to SMA after P. falciparum infection. We hypothesized that underlying
genetic factors that influence hemoglobin regulation and production contribute to the
phenotypic outcomes of SMA. This includes the amelioration of a population specific αthalassemia 3.7kb deletion, in combination with HBA2 genotypes and haplotypic
constructs. Children who were enrolled in this study were evaluated for falciparum,
bacterial, and HIV-1 infections, as well as a full clinical evaluation that included tests for
common genetic diseases (G6PD, HbS) within the sub-Saharan population. These
measures were corrected and controlled for in our regression model due to possible
influences on disease outcomes, specifically anemia. For instance, anemia is a hallmark
of both HIV-1 infection (Oteino 2006, Bailey 2015) and Sickle-cell disease (Chakravorty
2015).

Hypoglycemia, respiratory stress, and hyperparasitemia

also contribute to

falciparum related disease, but severe anemia in children is often the result in
holoendemic infection regions such as western Kenya (Perkins 2011 review) where
cerebral malaria is a rare occurrence (Ongecha 2006 Novelli 2010).
This study examined the role of HBA2 SNPs (-1789C/T, rs2974771 and 4314A/G, rs1203833) in combination with the -α3.7thalassemia deletion, and their
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individual and combined influence on severe malarial anemia. HBA2 functionally codes
for one of two alpha globin chain in hemoglobin and is expressed 2-3 fold higher than the
HBA1 counterpart (Liebhaber 1986). As such, HBA2 gene expression is paramount to
proper hemoglobin synthesis. Furthermore, polymorphic variation within the coding, as
well as promoter regions of HBA2 has been characterized within α-thalassemia disease
(Megawati 2014, Qadah 2014, Hamid 2014) where anemia is a key clinical finding.
Megawati et. al., investigated a novel mutation within the coding region of HBA2 that
was found prenatally in a Sudanese family that had a history of α-thalassemia (Megawati
2014). Another study characterized three HBA2 promoter variants (HBA2 -59C>T,81C>A, and -91G>A) in transcription and translation in α-thalassemia patients.
Investigators found that in vivo, HBA2 -59C>T and -91G>A, mutations were significantly
associated with HBA2 transcript levels (Qadah 2014). A novel nonsense mutation (HBA2
c.382A>T) was found in a smaller study (n=4) of α-thalassemia patients in Iran. This
study found that carriers the nonsense mutation had microcytic anemia and moderate
hypochromia. Furthermore, these individuals were unrelated, but were of the same ethnic
group (Hamid 2014).

Previous findings by Ya et al, have shown that carriage of

rs2974771 (HBA2 -4314A/G) prenatally can be potentially used to diagnose αthalassemia (Ya 2011).
The manifestations of falciparum malaria are multifaceted with disease severity
influenced by many factors (e.g., co-infections, age, endemicity, ethnicity, nutrition, and
genetic variation (Perkins 2011 review).
Several studies have attempted to bridge the understanding of malarial infection
and α-thalassemia disease (Opoku-Okrah 2013, Mockenhaupt 2004, Williams 2005,
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Allen 2007, Evenvold 2008).

This study was designed to help further unravel the

complexity of hemoglobinopathies by using our discovery of novel variation in HBA2 in
the context of α-thalassemia for examination of the influence of the individual and
combined variants on susceptibility to SMA. Protection against severe malaria disease is
a characteristic that α-thalassemia has been associated with in several populations
worldwide (Wambua 2006, May 2007, Williams 2005, Allen 1996, Mockenhaupt 2004,
Fowkes 2008). The α-thalassemia genotype for our cohort was distributed as 43% normal
(αα/αα), 37% heterozygous (-α/αα), and 20% homozygous deletions (-α/-α) (P=0.016).
A study in 382 children living off the coast of Kenya showed similar distributions [32%
(αα/αα), 49% (-α/αα), and 19% (-α/-α)] for the α-thalassemia trait (Wambua 2006).
Williams et. al., described a large study for the same Kenyan coastal cohort where
homozygous and heterozygous carriers (-α/-α and -α/αα) were associated with reduced
risk for severe disease (Williams 2005). In contrast to the study presented, Wambua and
Williams et. al., showed a significant association with α-thalassemia and severe malaria
disease outcomes (Wambua 2006). We found 30% protection against overall parasitemia
(Table 4) in children with the -α3.7kb deletion (-α/-α) that was borderline significance
(P=0.07), but no association with the -α3.7kb and susceptibility to SMA was discovered.
In a large prospective study of Thai children (<120 mos.) infected with falciparum
malaria, there was a strong link between severe anemia and cerebral malaria with (-α/αα
and -α/-α) carriers (May 2007). The investigators suggested that the anemic association
with α-thalassemia carriers seen in their study was due to the hypoxic effects of
abnormally low hemoglobin that is often countered by a significant increase in
erythrocyte overcompensation. Another study that examined the anemic findings in a
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Papau New Guinea pediatric population with malaria found significantly reduced Mean
Cell Volume (MCV), Mean Cell Hemoglobin (MCH), and Hemoglobin (Hb) (Fowkes
2008). Our study showed similar findings overall when examining these measures in αthalassemia carriers alone. We extended previous findings by others in our study by
examining an inefficient erythropoietic response (RPI<2) as a categorical outcome
variable in the logistic regression models. When examining polymorphic variation within
the promoter of HBA2, children with homozygous wild-type haplotypic constructs
(HBA2-1789/-4134 CG) are significantly more likely to get SMA, whereas their
homozygous polymorphic counterparts (HBA2-1789/-4134 TA) are significantly less
likely to develop the disease. Furthermore, we discovered that children who are carriers
of the homozygous -1789 C/T (C) allele and -α3.7kb deletion (C/-α) are 3-times more
likely to develop SMA. In addition, when a child is also a carrier of the -4134 G/A (G)
allele and -α3.7kb deletion (CG/-α), they are more susceptible to SMA and have a 2-fold
greater risk of an inefficient erythropoietic response. Conversely, those who are carriers
of the polymorphic TA/-α haplotype are protected against SMA, but have (2-fold)
reduced erythroid response.
In conclusion, anemia induced by falciparum malaria can result from both
dysregulation in erythroid function and hemolysis of RBCs through parasite invasion
(Perkins Review 2011, Menendez 2000). Furthermore, anemia in the context of αthalassemia diseases has been shown in several studies. Data presented here demonstrate
that α-thalassemia, in concert with polymorphic variation within the HBA2 promoter,
significantly influence severe malaria disease outcomes, specifically anemia and
erythropoietic responses.

Results from this study further illustrate the impact of
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hemoglobinopathies and polymorphic variation within genes that regulate hemoglobin on
susceptibility to malaria and the differing nature of these variants on disease outcomes in
regions with holoendemic P. falciparum transmission.
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TABLE AND FIGURE LEGENDS
Table 4.1. Demographic, laboratory and clinical measures of parasitemic
children enrolled in the study.
Data are represented as median (IQR). Children with acute malaria at the Siaya District
Hospital were stratified into two groups: non-severe malarial anemia (Non-SMA; Hb≥5.0
g/dL) and severe malarial anemia (SMA; Hb<5.0 g/dL).
of gender was determined using Chi-square test.

b

a

Differences in the proportion

Differences in the median ages,

parasitemia, red blood cell (RBC) counts, hemoglobin levels and reticulocyte production
index (RPI) between the groups were determined using Mann-Whitney U test.

Table 4.2. Distribution of HBA2 genotypes and α-Thalassemia deletions in
children with malaria.
Data are shown as proportion (n,%) of children into aparasitemic, parasitemic, non-SMA
and SMA groups. Children were categorized based on P. falciparum malaria infection
and according to SMA classification with SMA status (Hb < 5.0 g/dL) and non-SMA
status (Hb > 5.0g/dL). Chi-Square test was used to determine differences in proportions
and significance was set at P<0.05.

Table 4.3. Distribution of HBA2 promoter and α-Thalassemia deletions
haplotypes in children with severe malarial anemia.
Data are shown as proportion (n,%) of children into aparasitemic, parasitemic, non-SMA
and SMA groups. Children were categorized based on P. falciparum malaria infection
and according to SMA classification with SMA status (Hb < 5.0 g/dL) and non-SMA
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status (Hb > 5.0g/dL). Children were further stratified according to their HBA2 and αThalassemia haplotypes where chi-Square test was used to determine differences in
proportions and significance was set at P<0.05.

Table 4.4. Figure 4.1 Cross-sectional association of HBA2 -1789C/T, HBA2 4314A/G and α-Thalassemia deletion haplotypes with SMA and RPI.
Binary logistic regression analyses were conducted in parasitemic children (n=1,314) to
determine relationship between HBA2 -1789C/T, HBA2 -4314A/G and α-Thalassemia
haplotypes and SMA (A) and and RPI (B) . For each test, the age, gender, HIV status,
bacteremia, sickle cell trait (HbAS), and G6PD deficiency status were controlled for in
the analyses.

Presented as odds ratio (OR; 95% confidence interval), with P<0.05

considered statistically significant.
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TABLES AND FIGURES
Table 4.1. Demographic, laboratory and clinical measures of parasitemic
children enrolled in the study.

Non-SMA
(Hb≥5.0
g/dL)

SMA
(Hb<5.0 g/dL)

P-value

Number, n

1053

261

N/A

Gender, %F:M

51:49

47:53

0.137

Age, months

12.8 (10.5)

10.0 (10.5)

<0.001

Admission Temperature, °C

38.0 (2.0)

37.5 (1.0)

0.026

7.6 (2.9)

4.2 (1.0)

<0.001

Red Blood Cell count, (10 /L)

3.7 (1.5)

1.8 (0.7)

<0.001

Hematocrit, (%)

25.1 (9.1)

13.9 (3.6)

<0.001

11.7 (6.4)

15.0 (9.8)

<0.001

46.4 (21.0)

50.9 (16.7)

0.001

7.9 (5.4)

9.0 (6.5)

<0.001

28,902 (79,044)

22,267 (63,516)

0.003

731 (79)

168 (64)

0.030

Absolute Reticulocyte Number (ARN)

1.4 (2.0)

2.8 (4.0)

0.007

Reticulocyte Production Index (RPI)

1.2 (1.6)

1.3 (2.1)

<0.001

RPI<2.0,n (%)

867 (86)

223 (91)

0.024

173 (16.4)

23 (8.9)

0.025

38 (4.2)

6 (2.9)

0.143

168 (22.5)

45 (19.2)

<0.001

HIV-1, n (%)

31 (3.9)

13 (5.2)

<0.001

Bacteremia , n (%)

98 (9.3)

21 (8.1)

0.225

Characteristic

a
b

Hematological Indices
Hemoglobin (g/dL)
12

3

White Blood Cell count (10 /µL)
3

Lymphocytes (10 /µL)
3

Monocytes (10 /µL)

b
b
b
b

b
b

Parasitological Indices
Parasitemia, MPS/µL
High Density Parasitemia (>10,000/µL) , n (%)

b
a

Reticulocyte Indices
b

a

Genetic Variants
Sickle Cell Trait, n (%)
Glucose-6-phosphate deficiency, n (%)
Alpha-Thalassemia Trait, n (%)

a
a
a

Co-infections
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a

a

Table 4.2. Distribution of HBA2 genotypes and α-Thalassemia deletions in
children with malaria.

Genotype

Aparasitemic

non-SMA

SMA

Total

HBA2 -4314 A>G
AA, n (%)

176 (60.9)

AG, n (%)
GG, n (%)

77 (26.6)
36 (12.5)

P-value
0.176

544 (55.2)

146 (54.7)

866 (56.2)

94 (35.2)
27 (10.1)

505 (32.7)
171 (11.1)

CC, n (%)

334 (33.9)
108 (10.9)
HBA2 -1789 C>T
140 (45.1)
444 (42.9)

134 (47.7)

718 (44.1)

CT, n (%)

109 (35.0)

409 (39.5)

101 (35.9)

619 (38.0)

TT, n (%)

62 (19.9)

183 (17.7)

46 (16.4)

291 (17.9)

0.408

α-Thalassemia
α/α, n (%)

113 (43.8)

382 (43.3)

98 (39.0)

593 (42.6)

α/-α, n (%)

77 (29.8)

337 (38.2)

104 (41.4)

518 (37.2)

-α/-α, n (%)

68 (26.4)

164 (18.6)

49 (19.5)

281 (20.2)
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0.016

Table 4.3. Distribution of HBA2 promoter and α-Thalassemia deletions
haplotypes in children with severe malarial anemia.

Haplotypes
HBA2 -1789C/-4134A

Carriers Frequency

non-Carriers Frequency

non-SMA

SMA

non-SMA

SMA

P-value

CA

0.78

0.22

0.79

0.21

0.66

CG

0.76

0.24

0.79

0.21

0.28

TA

0.82

0.18

0.77

0.23

0.01

TG

0.79

0.21

0.78

0.22

0.65

C/α

0.77

0.23

0.78

0.22

0.33

C/-α

0.77

0.23

0.78

0.22

0.33

T/α

0.79

0.21

0.76

0.24

0.15

T/-α

0.82

0.18

0.77

0.23

0.05

A/α

0.77

0.23

0.78

0.22

0.51

A/-α

0.77

0.23

0.78

0.22

0.46

G/α

0.80

0.20

0.77

0.23

0.12

G/-α

0.77

0.23

0.78

0.22

0.68

CA/α

0.77

0.23

0.78

0.22

0.49

CA/-α

0.76

0.24

0.78

0.22

0.27

CG/α

0.74

0.26

0.77

0.23

0.54

CG/-α

0.74

0.26

0.78

0.22

0.27

TA/α

0.79

0.21

0.77

0.23

0.36

TA/-α

0.89

0.11

0.77

0.23

0.00

TG/α

0.80

0.20

0.77

0.23

0.11

TG/-α

0.75

0.25

0.78

0.22

0.43

HBA2 -1789C/α-Thalassemia

HBA2 -4134A/α-Thalassemia

HBA2 -1789C/-4134A/α-Thalassemia
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Table 4.4 Cross-sectional association of HBA2 -1789C/T, HBA2 -4314A/G and
α-Thalassemia deletion haplotypes with SMA and RPI.

Genotype

CC

CT
TT
AA

Parasitemia
95% CI
Odds Ratio
HBA2 -1789 C>T
1.00
1.08
0.79-1.47
1.01
0.68-1.51
HBA2 -4314 A>G
1.00
-

AG

1.38

0.99-1.92

GG

1.01

0.63-1.61

P value

0.63
0.95

-

SMA
95% CI
Odds Ratio
HBA2 -1789 C>T
1.00
0.83
0.59-1.16
0.59
0.37-0.97
HBA2 -4314 A>G
1.00
-

0.053

1.13

0.81-1.59

0.98

0.98

0.57-1.68

α-Thalassemia

P value

0.27
0.04

-

RPI
95% CI
Odds Ratio
HBA2 -1789 C>T
1.00
1.09
0.73-1.64
0.68
0.42-1.10
HBA2 -4314 A>G
1.00
-

P value

0.68
0.114

-

0.48

1.12

0.74-1.69

0.59

0.93

0.84

0.46-1.51

0.56

α-Thalassemia

α-Thalassemia

α/α

1.00

-

-

1.00

-

-

1.00

-

-

α/-α

1.28

0.89-1.83

0.177

0.84

0.58-1.21

0.34

0.89

0.58-1.39

0.63

-α/-α

0.70

0.48-1.03

0.069

0.95

0.60-1.50

0.83

0.83

0.49-1.40

0.49
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Table 4.4/Figure 4.1 Cross-sectional association of HBA2 -1789C/T, HBA2 4314A/G and α-Thalassemia deletion haplotypes with SMA and RPI.

Haplotypes

SMA Odds Ratio

95% CI

P value

RPI Odds
Ratio

95% CI

P value

1.17
1.67
0.62
0.87

0.89-1.54
1.21-2.30
0.46-0.82
0.67-1.11

0.24
0.0017
0.001
0.26

0.96
2.15
1.28
0.86

0.70-1.31
1.26-3.67
0.91-1.79
0.64-1.14

0.78
<0.01
0.16
0.29

1.30

0.96-1.77

0.09

1.05

0.74-1.49

0.79

3.23

1.64-6.37

<0.01

1.22

0.73-2.02

0.45

0.80

0.62-1.04

0.08

1.00

0.73-1.36

0.99

0.29

0.18-0.48

<0.01

1.01

0.64-1.58

0.98

1.09

0.70-1.71

0.69

1.05

0.63-1.76

0.84

0.98

0.69-1.39

0.93

1.05

0.70-1.57

0.81

0.93

0.68-1.26

0.61

1.35

0.92-1.98

0.13

1.05

0.76-1.44

0.77

1.08

0.75-1.56

0.68

1.11

0.83-1.49

0.47

0.91

0.64-1.28

0.58

1.36

0.93-2.00

0.12

0.83

0.54-1.29

0.41

1.83

1.01-3.31

0.04

2.22

0.78-6.36

0.14

1.81

1.79-2.77

<0.01

1.84

1.02-3.65

0.04

0.73

0.53-0.99

0.04

1.15

0.79-1.66

0.46

0.32

0.16-0.63

<0.01

2.13

0.97-4.26

0.08

0.87

0.66-1.15

0.33

0.95

0.68-1.32

0.76

0.59

0.35-1.00

0.05

0.65

0.39-1.06

0.08

HBA2	
  -‐1789C/-‐4134A	
  
CA
CG
TA
TG
HBA2	
  -‐1789C/α-‐Thalassemia
C/α
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  -‐4134A/α-‐Thalassemia
A/α
A/-α
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HBA2	
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CG/α
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TA/α
TA/-α
TG/α
TG/-α
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ABSTRACT
The pathogenesis of severe malarial anemia (SMA) occurs as the result of increased red
blood cell (RBC) destruction and a decrease in RBC production and ultimately chronic
anemia. Previous studies from our laboratory have shown that dysregulation in
circulating pro- and anti-inflammatory mediators influence the development of SMA. In
this current study we postulate that malarial anemia pathogenesis is driven by key
inflammatory mediators such as (recombinant human) rhMIG, rhIP-10, and rhIFN-γ as
well as unknown factors in circulating in the serum from SMA category children. To test
this hypothesis we used a CD34+ hematopoietic stem cell

in vitro model for

investigating erythroid development in which cells were either contidioned with serum
from pediatric patients (non-SMA and SMA) or rhMIG, rhIP-10, and rhIFN-γ.
.Examination

of circulating inflammatory meditators (25-plex) in serum before the

treatment of the in vitro model with serum showed a significant reduction in MIG and IP10 in children with SMA. Results from the erythroid model indicated that treatment of
erythroid cells with rhMIG, rhIP-10, and rhIFN-γ as well as conditioning cells with
pooled serum from pediatric SMA patients (n=10) reduced the relative number of stage
specific markers (CD71+/CD45+ and CD71+/CD235a+) in the erythrocytic model.
These results reveal that complex nature of inefficient erythropoietic response in children
might in part be caused by inflammatory mediators found in circulation and serum.
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BACKGROUND
Severe malaria anemia (SMA, Hb<5.0 g/dL) is a hallmark of Plasmodium Falciparum
infection in sub-Saharan Africa (Perkins 2011). In this region, mortality and morbidly of
malaria infection has the highest health burden in young children. The onset of malaria
pathogenesis begins at the erythrocytic stage of the parasite infection where severe
disease can manifest as cerebral malaria or anemia (Haldar 2009). Malarial anemia is
multifaceted where immune as well as non-immune mechanisms work in concert to drive
pathogenesis. Altered erythropoietic responses and hemolysis of parasitized and nonparasitized erythrocytes by innate immune cells, along with cytokine-driven
inflammation are factors that contribute to malarial anemia (Were 2006, Keller 2009).
Several investigations have linked inflammatory mediators to dyserythropoiesis (Chasis
2006, Awandare 2010) where the erythroid lineage development is disrupted or impaired.
For example, studies have shown that increased production of IL-6 alters hepcidin
expression, which results in fewer iron stores accessible for erythrocyte formation (Wang
2011). The proinflammatory cytokine, TNF-α, has been shown to regulate the GATA-1
erythrocytic transcription factor (Singh 2000), and mitigate parasite replication during
active infection (Kwiatkowski 1989). Another proinflammatory cytokine, IFN-γ,
provides protective effects against malaria in children and in experimental human P.
falciparum infections (D'Ombrain 2008, Pombo 2002). However, in severe disease states,
over-expression of such proinflammatory cytokines can lead to hyper-activation of the
innate immune response, stimulating inflammation in the peripheral tissue, damaging
bone marrow, and eventually causing loss of functional erythrocytic cells (Clark 2003).
The chemoattractant cytokines (Chemokines), MIG and IP-10 play a vital role in the IFN-
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γ proinflammatory pathway. They are both secreted by IFN-γ activated neutrophils,
monocytes, fibroblasts and endothelial cells, and act as a positive feedback mechanism
for inflammation (Jinquan 2000, Rossi 2000, Taub 1999).
Previous examinations have shown that rhMIG negatively influences erythroid
progenitors from primary bone marrow cultures (Schwartz 1997). A study by DickinsonCopeland et al (2015) indicated a strong relationship between suppression in erythroid
cells in older Ghanaian children with malaria and increased production of circulating
IP10 through heme-driven apoptosis. Several studies from our laboratories and others
have shown a hemozoin-driven model of cytokine/chemokine dysregulation that results
in erythropoietic suppression in children with the SMA phenotype (Awandare 2007 2010,
Cascals-Pascual 2006). Additional studies have also shown that inflammatory mediator
activation through phagocytosis of hemozoin results in an anemic state (Ongecha 2008,
Were 2009).).
The development of an in vitro erythropoietic model by our group (Awandare
2010) avoids the ethical and practical difficulties of obtaining bone-marrow aspirates
from children to isolate erythroid progenitor cells. The model relies on isolation and
culture of CD34+ cells from peripheral blood from malaria-naïve donors, followed by the
induction of erythroid progenitors with soluble mediators that promote erythroid
development. Studies conducted here utilized the in vitro model of erythropoiesis to
examine the influence of chemokines (MIG and IP-10), cytokines (IFN-γ), patient serum
isolated from children with malaria (non-SMA and SMA).
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MATERIALS AND METHODS
Clinical Measures
Study participants. Children aged 3-36 mos. (n=20) presenting with P. falciparum
malaria at Siaya County Hospital were recruited for the study. Children with nonfalciparum malaria species, cerebral malaria, co-infections (HIV-1 or bacteremia), sicklecell anemia, and α-thalassemia deletions and glucose-6-phosphate dehydrogenase
deficiency were not included in the study. The study site and population has been
described in detail by (Ong’echa 2006).
Sample collection and laboratory evaluation. 1-3 mL of venous blood was obtained
from each child enrolled in the study where hematological measures, including a
complete blood count (CBC) were determined. A fraction of blood was also centrifuged
to isolate serum, which was snap frozen and stored at -80oC. Parasitemia was determined
by thin and thick blood smears prepared from finger/heal prick blood (~100uL). Blood
smears were then stained for microscopy with Giemsa reagent (Sigma), trophozoites were
counted against 300 leukocytes, and parasite densities estimated using the WBC counts
from the CBC. Sample collection and laboratory evaluation procedures are previously
described here (Novelli 2010).
Determination of circulating cytokines and chemokines. Plasma samples obtained from
venous blood were stored at -70°C until use. Soluble mediator concentrations were
determined using the Human Cytokine Twenty-Five-Plex Antibody Bead Kit (Invitrogen
International), in accordance with the manufacturer’s instructions. Plates were read on a
Luminex 100 system (Luminex) and analyzed using Bio-Plex Manager software (version
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IS 2.3; Bio-Rad Laboratories).
CD34+ Cell Isolation. CD34+ cells were enriched from peripheral blood mononuclear
cells (PBMCs) that were isolated from whole blood leukopaks (500mL) from malarianaïve donors using protocols approved by the University of New Mexico Institutional
Review Board. PBMCs were separated from whole blood using ficoll-plaque (GE
Healthcare Life Sciences) gradient separation. Cells were washed and suspended in
phosphate buffered saline solution (PBS, 0.5% bovine serum albumin, 0.6%
anticoagulant citrate dextrose). CD34+ progenitor cells were enriched from PBMC
populations using anti-CD34 magnetic microbeads and magnetic separator columns per
the manufacturer’s recommendations (Miltenyi Biotec, Auburn, CA). CD34+ purity was
determined to be >90% after isolation.
Erythroid progenitor cell lineage growth media. Basic cell culture media for CD34+
cells used in this study was based on previous methods (Awandare 2010, Freyssinier
1999, Neildez-Nguyen 2002) and contained Iscove’s Modified Dulbecco’s Medium
(IMDM, Invitrogen), 15% BIT Serum Substitute (Stem Cell Technologies), 100U/mL
penicillin/streptomycin (Sigma), and 2 mM L-glutamine. Secondary culture contained
basic media 10 ng/mL interluken-3 (IL-3), 10 ng/mL IL-6, and 100 ng/mL stem cell
factor (SCF) (R&D Systems). Erythrocytic lineage induction media was added at day 3
and contained 1.0 U/mL erythropoietin (R&D Systems). CD34+ cells were plated into
12-well plates at 1.5x105 cells/well and incubated at 37° C with 5% CO2, 5% O2
(balanced with N2) in a humidified chamber. Viable cell counts were determined by
trypan blue staining.
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Serum conditioned media and CD34+ cell Treatment. Serum was pooled from children
with non-SMA (n=10) and SMA (n=10) and then added to secondary media (described
above) at 5% of the total serum concentration. Pooled serum in media was then added to
CD34+ cells at day 3 for the respective conditions.
Cell Viability. Cell viability was determined using the CellTiter Glo ® (Promega) assay
per the manufactures recommended methods and protocol. 50,000 cells from CD34+
assayed conditions were added to prepared CellTiter-Glo® Reagent in 96-well plates
(duplicate) and rocked gently at room temperature for 15 minutes to induce cell lysis.
Luminescence counts per second (CPS) for samples was determined using the
PerkinElmerTM Victor 3 1420 Multilabel Counter plate reader and data were captured
using Wallac 1420 Workstation (Perkin Elmer, MA USA).
Immunophenotyping. At days 7, 10, and 14, cell surface markers were stained using
conjugated antibodies [CD34 (MACs), CD45, CD71, and CD235a [Glycophorin A
(GPA); Invitrogen] and then measured by flow cytometry. Cells were also concurrently
stained for viability using 7-amino actinomycin (7AAD; eBioscience) DNA antibody.
Cells were suspended in 0.5% BSA/PBS and incubated with respective antibodies for 25
minutes at 4°C. Following incubation, cells were washed twice and fixed in 1%PFA/PBS
for flow cytometric capture. Populations were measured using the BD Fortessa flow
cytometer and analyses were conducted using Flowjo (v7) software.
Statistical analyses. Non-parametric data were compared by Chi-square test and MannWhitney U test between treatment and disease categories for the different conditions.
Data presented in this study for cell culture experiments are representative of three
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independent experiments conducted in duplicate. Treatment conditions (EPO, non-SMA,
and SMA) were compared and tested for statistical significance using analysis of variance
(ANOVA) and students T-test, and normalized relative to EPO treatments. Statistical
analyses for serum samples from children were performed using SPSS software (version
19.0), whereas cell culture experiments were amalyzed using GraphPad Prism 5 software.
Statistical significance was set at as P<0.05.

RESULTS
Clinical characteristics of the study participants (Table 5.1)
Children (n=20) with active P. falciparum infections were stratified into nonSMA (Hb<5.0 g/dL, n=10) and SMA (Hb>5.0 g/dL, n=10) based on Hb levels. The
clinical characteristics of the study participants from whom serum was isolated are
summarized in Table 1. There was a non-significant difference in gender distribution
with slightly more females than males in the two groups (P=0.085). Children with SMA
were significantly younger (P=0.016), and based on the grouping strategy had lower
hemoglobin (Hb), red blood cell (RBC) count, and hematocrit. The white blood cell
(WBC), lymphocyte and monocyte counts were elevated in children with SMA (P<0.001,
P<0.005, and P<0.001). Peripheral parasitic burden was lower in the non-SMA group
(P< 0.01). The reticulocyte production index (RPI) was lower in children with SMA
(P<0.001), whereas an RPI<2 (a corrected indicator of inefficient erythrocyte production)
was higher in this group (P<0.001).
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Circulating inflammatory mediators (25-plex) (Figure 5.1)
Levels of circulating (plasma) soluble mediators for children (non-SMA and
SMA) who donated serum were examined using a human cytokine 25-plex-bead kit.
From the panel of 25 mediators, four proteins were significantly different across the
groups. IL-12 [non-SMA Median: 443.23, IQR: 550.23; SMA Median: 239.26, IQR:
301.23, (P=0.009)], IL-10 [non-SMA Median: 790.48, IQR: 921.02; SMA Median:
185.75, IQR: 207.37, (P=0.004)], MIG [non-SMA Median: 221.41, IQR: 285.26; SMA
Median: 109.62, IQR: 125.26, (P=0.007)], and IP-10 [non-SMA Median: 708.23, IQR:
810.97; SMA Median: 327.82, IQR: 365.24, (P<0.001)] were all down-regulated in
children with SMA.

Gating Strategy (Figure 5.2)
Forward (FSC) and side (SSC) scatter plots were generated for CD34+
populations. Viable cell populations were selected by gating for cell debris (or doublets)
by selecting events that were higher in FSC and lower in SSC versus non-viable cells
found in the lower portions of both FSC, and some portions of higher SSC. Thus, viable
cell populations were selected based on higher FSC and lower SSC. To verify that live
events were (indeed) captured, a viability stain, 7AAD, was added to flow cytometry
panels (see methods). This particular marker binds free DNA which generated by lysed or
dead cells, thus, leaving live (viable) cell populations unstained. The final selection
strategy for live populations involved gating off of 7AAD+ cells with negative selection.
A typical representation of these experiments is shown in Figure 5.3 in which 62.2% of
the live population was selected.
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Effects of SMA and non-SMA serum on erythroid cell populations (Figures
5.3 and 5.4)
Children with SMA have been shown to have altered erythropoiesis by several
mechanisms Wickramasinghe 2000, Nussenblatt 2001, Fowkes 2008, Awandare 2011,
Anyona 2012). To further our understanding of the erythropoietic process, the in vitro
model was exposed to pooled serum from children with non-SMA (n=10) and SMA
(n=10). Erythroid development was characterized by examining cell surface markers as
defined in Figure 5.3. Specifically, CD45, CD71, and CD235a were examined. CD45
(leukocyte common antigen) is a glycoprotein that is present on immature erythroid cells
and is lost with progression to later lineages. CD71 (transferrin receptor) regulates the
uptake of transferrin-iron and gradually increases throughout erythroid lineage until it
declines after D12.

CD235a (glycophorin a receptor) is an erythrocytic membrane

protein that increases around D10 where it continues to rise, indicating later-stage
erythroid lineages. Cells were treated with IL-3, IL-6, and SCF at D0 to induce erythroid
lineage development. EPO was then added on D3, and every three days thereafter, to
enhance lineage development. In addition, the pooled serum (non-SMA and SMA) and
control serum were added to the cultures at D3. The first measurement of erythroid
lineage markers was performed by flow cytometry on D7. Experimental conditions were
compared to the control serum with EPO. As shown in Figure 5.4, the CD71+/CD45+
cell population was significantly lower in cultures treated with serum from children with
SMA on D7 (P<0.05), and significantly lower for both non-SMA and SMA serum on D1
and 14 compared to the EPO control (P<0.05). Cells expressing CD71+/CD235a+ were
significantly lower in cultures treated with serum from children with SMA at all time

94

points, and higher, but still significantly reduced in response non-SMA serum relative to
EPO (P<0.05).

Effects of inflammatory mediators on erythroid cell populations (Figure 5.5)
Previous investigations have shown that pro-inflammatory mediators influence
both the erythropoietic response and hemolysis which culminate in the development of
anemia. As such, we investigated the influence of three pro-inflammatory mediators,
MIG, IP-10, and IFN-γ to determine their impact on erythroid development.
Consistent with the experiments outlined above with serum from children with
malarial anemia, cultures were treated MIG, IP-10, and IFN-γ on D3, and erythroid cell
development was measured with stage-specific markers until D14.
CD71+/CD45+ populations were normally distributed (39-43%) for all treatment
conditions when normalized and compared to EPO. At D10, IP-10 treated cells were
significantly lower (76%) when compared to IFN-γ (90%), MIG (91%) and EPO
conditions (P< 0.05). A similar result was seen at D14, even though IP-10 treated cells
recovered to about 80%. In addition, CD71+/CD235+ populations were examined after
pro-inflammatory mediator treatments. IP-10 and MIG treated cells (36-40%) were
significantly lower at D7 when compared the IFN-γ treatment, as well as to normalized
EPO control cells. MIG treated cells were 90% CD71+/CD235+ at D10 when compared
to IP-10 (78%) and IFN-γ treatments. By D14, IFN-γ, IP-10, and MIG conditions were
75%, 80%, and 84% for CD71+/CD235+ cells when compared to the EPO treated control
condition (P<0.05).
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Effects of SMA and non-SMA serum conditioned media and inflammatory
mediators on erythroid cell viability (Figure 5.6)
Erythroid lineage cells were examined and monitored at D7, D10 and D14 for
viability after disease category serum treatment as well as inflammatory mediator
stimulation independently. Cells grown in the presence of SMA serum were significantly
less viable (60%: D7, 48%: D10, 18%: D14, P<0.05) at all three time-points examined,
and had a marked decrease in viability by D14 when compared to non-SMA conditions
(80%: D7, 82%: D10, 61%: D14, P<0.05) and both were also significantly less viable
throughout the course when compared to EPO control cells. At D7, mediatory treated
cells (IFN-γ, MIG, IP-10) had a marked decrease (71%, 75%, 67% respectively) in
viability but increased in viability by D10 (91%, 88%, 80%). This increase was limited
though and cell viability was reduced (79%, 87%, 78%) by D14.
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DISCUSSION
Erythropoietic dysfunction during malarial infection in young children leads to a
severe anemic state. We and others have described several pathways in which
dyserythropoiesis is a key aspect of SMA pathogenesis (Were 2006, Awandare 2011,
Keller 2009 OTHERS). While there are still significant gaps in our understanding of
SMA pathogenesis, it is clear that immunity plays a vital role in directly regulating
erythropoietic functions (Were 2006, Awandare 2011, Keller 2009, Lyke 2003, Anyona
2011, Ong’echa 2011, Ouma 2010). To overcome the difficulties of understanding the
basic aspects of erythropoiesis, we have developed a novel model of erythroid lineage
development in which we stimulate CD34+ cells isolated from peripheral blood with
specific grow factors (Awandare 2011, Freyssinier 1999, Neildez-Nguyen 2002). This
model of erythropoiesis is advantageous in that we are able to use readily available
immunophenotyping techniques, as well as viability assays to monitor lineage without the
necessity of relying on bone marrow aspirates.
Previously, our investigations and others have shown the influence of
inflammatory mediators such as TNF-α, IL-12, Nitric Oxide (NO), MIF, and IFN-γ on
severe disease outcomes in children with malaria (Singh 2000, Keller 2004, Awandare
2006, Ongecha 2011, Clark 2003, Lyke 2004). Furthermore, increased chemokines in
plasma such as IL-8, MIP1-α, and RANTES have been linked to malarial pathogenesis.
(Were 2006, Kremsner 1995, Burgmann 1995, Lyke 2004). As such, the mediators that
are present within serum and/or plasma appear to directly contribute to disease outcomes.
Based on this rationale, we utilized pooled serum at physiological concentrations from
two disease categories (children with SMA and non-SMA) in our model system to
97

determine the impact on soluble mediators on the erythropoietic response with
immunophenotyping and cell viability assays.
The clinical aspects of the serum samples that were pooled from the study
participants can be found in Table 1. Children from the non-SMA group had significantly
different indices of anemia (P<0.01), characterized by better hematological indices and
more efficient erythropoiesis (RPI>2). Consistent with the selection criteria, results from
the in vitro model showed a significantly delayed erythropoiesis in cultures treated with
serum from children with SMA that was revealed upon measurement of CD235a and
CD71 at 7, 10 and 14 days after induction of erythroid development. Moreover, there
was also a loss in the leukocyte antigen marker, CD45, further confirming a delay in
erythrocyte maturation. It is important to note that both non-SMA and SMA serum
displayed maturational delays compared to the mock (EPO only control) cell populations.
However, the results were more pronounced in children with SMA.
Additional experiments under the same conditions were used to investigate the
importance of IFN-γ, IP10, and MIG on erythroid development. When cells were treated
with IFN-γ, IP10, and MIG, only cultures treated with IP10 recovered by D14. This result
in the context of reduced IP10 in the pooled serum from children with SMA suggests that
reduced IP10 may be central to the erythoid development deficiencies observed in this
group of children.
We also examined the viability of cells at different time points in the erythrocyte
model. These experiments demonstrated that cultures treated with SMA serum, IFN-γ,
IP10, and MIG treated cells were significantly less viable through the entire time course.
This signifies that serum from severely ill children, as well as specific inflammatory
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mediators can cause cell maturation dysfunction and delays in maturation as indicated
through immunophenotyping. Several previous reports suggest that chemokines,
specifically MIG and IP10, alter erythrocyte maturation and influence the pathogenesis of
severe malaria (Schawartz 1997, Dickenson-Copeland 2015, Ongecha 2011). The key
proinflammatory type-1 cytokine, IFN-γ, acts directly on both MIG and IP10 signaling
pathways and has been characterized as a major cytokine in immunopathogenesis
(D'Ombrain 2008, Pombo 2002). Results from this study suggest that the influence of
these pathways is also important in erythroid development. Here, we demonstrate that
serum from children with SMA, as well as specific mediators known to influence disease
pathogenesis (i.e., MIG, IP10, and IFN-γ) impact on erythroid cell maturation and cell
viability. Taken together, results presented here support our hypotheses that inefficient
erythropoietic responses in children with malaria are associated with inflammatory
mediators found in circulation during an active infection.
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TABLE AND LEGENDS	
  
Table 5.1. Clinical characteristics of the Study Participant Serum.
Parasitemic	
   children	
   (n=20)	
   were	
   categorized	
   into	
   SMA	
   (Hb<5.0	
   g/dL)	
   and	
   non-‐SMA	
  
(Hb≥	
   5.0	
   g/dL)	
   according	
   to	
   WHO	
   guidelines.	
   Data	
   are	
   presented	
   as	
   the	
   median	
  
(Interquartile	
   range,	
   IQR)	
   unless	
   stated	
   otherwise.	
   Reticulocyte	
   production	
   index	
   (RPI)	
  
were	
   calculated	
   using	
   previously	
   described	
   methods	
   (reticulocyte	
   index	
   (RI)=	
  
(reticulocyte	
  count	
  x	
  hematocrit)/30.7	
  (average	
  hematocrit	
  of	
  children	
  <5.0	
  years	
  of	
  age	
  
in	
   Siaya	
   County);	
   maturation	
   factor	
   (MF)=	
   1+0.05(30.7-‐hematocrit);	
   RPI=RI/MF;	
   Were	
  
2009)	
   	
   aChi-‐Square	
   test	
   was	
   used	
   to	
   determine	
   differences	
   in	
   proportions.	
   b	
   Mann-‐
Whitney	
   	
   test	
   	
   was	
   used	
   to	
   determine	
   differences	
   in	
   medians.	
   P<0.05	
   was	
   considered	
  
significant.	
  

Figure 5.1. Circulating chemokine levels in parasitemic children.
Concentrations	
   of	
   chemokines	
   (pg/mL)	
   were	
   measured	
   in	
   plasma	
   from	
   children	
   <3.0	
  
years	
   with	
   P.	
   falciparum	
   malaria	
   using	
   a	
   Human	
   Cytokine	
   25-‐plex	
   Antibody	
   Bead	
   Kit	
   and	
  	
  
Luminex®	
  100™	
  system	
  (See	
  materials	
  and	
  methods	
  for	
  description).	
  Concentrations	
  of	
  
circulating,IP-‐10,	
   and	
   MIG	
   (pg/mL)	
   in	
   children	
   (n=20)	
   were	
   categorized	
   into	
   SMA	
   	
   (n=10)	
  
and	
   non-‐SMA	
   (n=10)	
   groups	
   based	
   on	
   the	
   WHO	
   definition	
   of	
   SMA	
   (i.e.,	
   Hb	
   <5.0	
   g/dL,	
  
with	
   any	
   density	
   of	
   parasitemia).	
   Box-‐plots	
   depict	
   the	
   data	
   where	
   the	
   box	
   represents	
  
the	
  interquartile	
  range,	
  the	
  line	
  through	
  represents	
  the	
  median,	
  and	
  whiskers	
  represent	
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the	
   10th	
   and	
   90th	
   percentile.	
   When	
   compared	
   to	
   the	
   non-‐SMA	
   group,	
   circulating	
   MIG	
  
and	
   IP10	
   are	
   significantly	
   reduced	
   in	
   the	
   SMA	
   category	
   (P<0.005	
   and	
   P<0.001	
  
respectively)	
  
Differences	
  between	
  groups	
  were	
  compared	
  by	
  Mann-‐Whitney	
  U	
  test.	
  

Figure 5.2. In Vitro Model of erythropoiesis.
Hemaptopoetic	
  progenitor	
  cells	
  (CD34+)	
  were	
  isolated	
  from	
  peripheral	
  donor	
  blood.	
  
CD34+	
  cells	
  were	
  positively	
  selected	
  from	
  other	
  cell	
  types	
  using	
  a	
  magnetic	
  anit-‐CD34+	
  
conjugated	
  antibody	
  platform	
  (see	
  materials	
  and	
  methods).	
  	
  CD34+	
  cells	
  were	
  expanded	
  
into	
  erythroid	
  lineage	
  for	
  three	
  days	
  	
  using	
  rhIL-‐3,	
  rhIL-‐6,	
  and	
  rhSCF.	
  At	
  day	
  3	
  media	
  was	
  
replaced	
  with	
  complete	
  stem-‐cell	
  media	
  containing	
  	
  EPO,	
  rhIL-‐3,	
  rhIL-‐6,	
  and	
  rhSCF	
  and	
  
patient	
  serum	
  (non-‐SMA	
  and	
  SMA)	
  or	
  rhMIG,	
  rhIP10,	
  and	
  rhIFN-‐γ	
  for	
  respective	
  
experiments.	
  Cells	
  were	
  collected	
  at	
  days	
  7,	
  10,	
  and	
  14	
  cells	
  in	
  which	
  
immunophenotyping	
  and	
  cell	
  viability	
  assays	
  were	
  conducted.	
  

Figure 5.3. Gating Strategy.
CD34+	
  cells	
  were	
  stimulated	
  with	
  EPO,	
  rhIL-‐6,	
  rhIL-‐3,	
  and	
  rhSCF.	
  Cells	
  were	
  then	
  stained	
  
for	
  CD45,	
  CD71	
  ,	
  and	
  CD235	
  markers	
  a	
  Day	
  7,	
  10,	
  and	
  14.	
  Populations	
  were	
  measured	
  
using	
   the	
   BD	
   Fortessa	
   flow	
   cytometer	
   and	
   analysis	
   was	
   conducted	
   using	
   Flowjo	
   (v7)	
  
software.	
   Erythroid	
   progenitor	
   cell	
   flow	
   cytometry	
   plots	
   were	
   generated	
   from	
   live	
   cell	
  
populations	
  using	
  7AAD	
  for	
  negative	
  selection.	
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Figure 5.4. Effects of SMA and non-SMA serum conditioned media on
erythroid cell populations
CD34+	
   cells	
   were	
   stimulated	
   with	
   EPO,	
   IL-‐6,	
   IL-‐3,	
   and	
   SCF	
   and	
   then	
   conditioned	
   with	
   5%	
  
pooled	
   serum	
   from	
   non-‐SMA	
   (Hb>5.0	
   g/dL)	
   and	
   SMA	
   (Hb<5.0	
   g/dL)	
   children	
  
respectively.	
  Cells	
  were	
  then	
  stained	
  for	
  CD45,	
  CD71	
  ,	
  and	
  CD235	
  markers	
  a	
  Day	
  7,	
  10,	
  
and	
  14.	
  Populations	
  were	
  measured	
  using	
  the	
  BD	
  Fortessa	
  flow	
  cytometer	
  and	
  analysis	
  
were	
   conducted	
   using	
   Flowjo	
   (v7)	
   software.	
   Data	
   represented	
   as	
   normalized	
   to	
   EPO.	
  
Treatment	
   conditions	
   (EPO,	
   non-‐SMA,	
   SMA)	
   were	
   compared	
   and	
   tested	
   for	
   statistical	
  
significance	
   using	
   analysis	
   of	
   variance	
   (ANOVA)	
   and	
   students	
   T-‐test	
   and	
   normalized	
  
relative	
  to	
  EPO	
  treatments.	
  Significance	
  was	
  determined	
  at	
  P<	
  0.01*.	
  

Figure 5.5. Effects of inflammatory mediators on erythroid cell populations.
CD34+	
  cells	
  were	
  stimulated	
  with	
  EPO,	
  IL-‐6,	
  IL-‐3,	
  and	
  SCF	
  and	
  then	
  treated	
  with	
  rhIFN-‐γ,	
  
rhIP10,	
  and	
  rhMIG.	
  Cells	
  were	
  then	
  stained	
  for	
  CD45,	
  CD71	
  ,	
  and	
  CD235	
  markers	
  a	
  Day	
  
7,	
   10,	
   and	
   14.	
   Populations	
   were	
   measured	
   using	
   the	
   BD	
   Fortessa	
   flow	
   cytometer	
   and	
  
analysis	
  were	
  conducted	
  using	
  Flowjo	
  (v7)	
  software.	
  Data	
  represented	
  as	
  normalized	
  to	
  
EPO.	
   Treatment	
   conditions	
   (EPO,	
   non-‐SMA,	
   SMA)	
   were	
   compared	
   and	
   tested	
   for	
  
statistical	
   significance	
   using	
   analysis	
   of	
   variance	
   (ANOVA)	
   and	
   students	
   T-‐test	
   and	
  
normalized	
  relative	
  to	
  EPO	
  treatments.	
  Significance	
  was	
  determined	
  at	
  P<	
  0.01*.	
  

Figure 5.6. Effects of SMA and non-SMA serum conditioned media and of
inflammatory mediators on erythroid cell viability.
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CD34+	
   cells	
   were	
   stimulated	
   with	
   EPO,	
   IL-‐6,	
   IL-‐3,	
   and	
   SCF	
   and	
   then	
   treated	
   with	
  
100ng/mL	
   of	
   IFNγ,	
   IP10,	
   and	
   MIG.	
   Cells	
   were	
   harvested	
   at	
   days	
   7,	
   10,	
   and	
   14	
   and	
   cell	
  
viability	
  was	
  measured	
  by	
  luminescence	
  using	
  the	
  CellTiter-‐Glo	
  assay.	
  Data	
  represented	
  
as	
  means	
  ±	
  SD	
  and	
  were	
  normalized	
  to	
  EPO.	
  Treatment	
  conditions	
  (EPO,	
  non-‐SMA,	
  SMA,	
  
rhIFN-‐γ,	
  rhIP10,	
  and	
  rhMIG)	
  were	
  compared	
  and	
  tested	
  for	
  statistical	
  significance	
  using	
  
analysis	
   of	
   variance	
   (ANOVA)	
   and	
   students	
   T-‐test	
   and	
   normalized	
   relative	
   to	
   EPO	
  
treatments.	
  Significance	
  was	
  determined	
  at	
  P<	
  0.01*.	
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Tables and Figures
Table 5.1. Clinical characteristics of the Study Participant Serum.

Characteristic

Non-‐SMA	
  Patients

SMA	
  Patients	
  

P	
  

10	
  

10	
  

N/A

40:60	
  

35:65	
  

12.0	
  (7.5)	
  
Median	
  (IQR)	
  

7.4	
  (5.4)	
  

0.085 	
  
b
0.016 	
  

	
  	
  	
  Hemoglobin	
  (g/dL)	
  

11.1	
  (0.4)	
  

4.4(0.7)	
  

<0.001 	
  

	
  	
  	
  RBC	
  	
  counts,	
  x	
  10 /L	
  

4.6	
  (0.56)	
  

1.7	
  (0.4)	
  

<0.001 	
  

	
  	
  	
  Hematocrit,	
  (%)	
  

33.7	
  (5.1)	
  

13.5	
  (2.3)

<0.001 	
  

	
  	
  	
  WBC	
  count	
  (10 /µL)	
  

12.1	
  (5.9)	
  

13.6	
  (4.6)	
  

<0.001 	
  

	
  	
  	
  Lymphocytes	
  (10 /µL)	
  

38.7	
  (27.2)	
  

54.5	
  (9.4)

<0.005 	
  

7.0	
  (4.7)	
  

11.4	
  (5.4)	
  

<0.001 	
  

Number,	
  n
Gender,	
  %F:M	
  
Age,	
  months	
  
Hematological	
  Indices	
  
12

3

3

3

	
  	
  	
  Monocytes	
  (10 /µL)	
  
Parasitological	
  Indices	
  
	
  	
  	
  Parasitemia,	
  MPS/µL	
  
Reticulocyte	
  Indices
	
  	
  	
  Reticulocyte	
  Production	
  Index	
  
(RPI)	
  
	
  	
  	
  RPI<2.0,n	
  (%)

44,455	
  (71,536)	
  

a

b
b
b
b
b
b

b

19,994(30,484)	
   <0.01 	
  
b

0.97(0)	
  

0.69(0.65)	
  

<0.001 	
  

8(80)	
  

10	
  (100)

<0.001 	
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Figure 5.1. Circulating Mediators Mulitplex Data in Kenyan Children for
Pulled serum.

P=0.009

P=0.004

P=0.007
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P=0.000

Count

Figure 5.2. Gating Strategy.
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Figure 5.3. In vitro model: Phenotypic Markers at different development
stages
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Figure 5.4. Effects of SMA and non-SMA serum conditioned media on
erythroid cell populations
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Figure 5.5. Effects of inflammatory mediators on erythroid cell populations.
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Figure 5.6. Effects of SMA and non-SMA serum conditioned media and of
inflammatory mediators on erythroid cell viability.
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6.0 CHAPTER SIX: CONCLUSIONS
CONCLUSIONS
The first study in this dissertation examined the influence of promoter variants for
the chemokines MIG and IP10 and their association with SMA. We used regression
analysis to show that variation within the promoter regions for MIG and IP10 (MIG560A/-1714T and IP-10-1447A/-1919T) is significantly associated with susceptibility or
protection against SMA. Several intragenic haplotypic constructs between promoters also
showed either an in increased susceptibility to SMA whereas or protection against. We
then examined erythropoietic response (RPI) in the context of SMA pathogenesis in
which we cross-referenced regression analyses between groups. This analysis showed
that 6 extended haplotypes had functional correlations between erythropoietic responses
and SMA in intragenic haplotype carriers. To further these findings we examined MIG,
IP-10 and IFN-γ which showed significant association of two extended haplotypes (GG
and GGG) with SMA and erythropoietic response and these inflammatory mediators.

The second study in this dissertation was focused on the the hemoglobinopathy αThalassemia and hemoglobin coding gene promoter variants (HBA2) in the context of
SMA. We were able to show protection against malaria infection (borderline significant;
P=0.07) in children with the -α3.7kb deletion (-α/-α); however, no association with the α3.7kb and SMA was seen independently. We also examined HBA2 promoter variants, α3.7kb deletion, and the combination haplotypes between deletion and promoter SNPs in
the context of SMA and erythropoietic response (RPI) using our regression model. In
this study, we found that carriers of homozygous wild-type haplotypic constructs (HBA2117

1789/-4134 CG) were significantly more likely to develop SMA. In contrast, their
homozygous polymorphic counterparts (HBA2-1789/-4134 TA) were significantly less
likely to develop SMA. We also found that that children who carried the homozygous 1789 C/T (C) allele and had the -α3.7kb deletion (C/-α) were likely to have SMA. When
considering erythropoietic response children who were carriers of the -4134 G/A (G)
allele and had the -α3.7kb deletion (CG-α), were more susceptible to SMA and have a 2fold decrease in erythropoietic response. These results demonstrate the influence of
polymorphic variability within hemoglobin genes and hemoglobinopathies on SMA
outcomes.

The third study in this dissertation examined the impact of MIG, IP10, and IFN-γ
recombinant proteins and pediatric malaria serum on erythroid lineage using an in vitro
model for erythropoiesis. We proposed that the mediators present in clinical serum
mediate disease outcomes and, as such, we used physiological serum concentration in our
model for erythropoiesis for each disease category: non-SMA and SMA serum. In a
similar fashion we treated this model with the chemokines MIG and IP10 as well as the
cytokine IFN-γ to examine their impact on erythroid lineage and viability. Our results
from these studies revealed that pediatric serum from children with SMA influenced cell
viability as well as erythroid lineage when we examined cell surface erythroid markers. A
similar result was also seen in cell populations that were treated with the inflammatory
mediators, MIG, IP10, and IFN-γ which reflected our proposal that serum from children
with SMA and inflammatory mediators ( MIG, IP10, and IFN-γ) infringe upon erythroid
cell maturation and viability in vivo. Together the results from these studies
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independently verify the influence of biomolecular markers and mediators on SMA
outcomes.

Future Directions and Implications
The results presented in this dissertation offer a genetic connection between the
biomolecular markers, MIG, IP-10, and HBA2 to clinical outcomes SMA pathogenesis.
This dissertation utilizes the information from a well-defined pediatric enrollment study
in combination in which clinical data, circulating mediator data, genetic variation data,
and regression analysis link phenotypic outcomes presented here (SMA and RPI<2.0).
Binary logistical regression analysis was performed in Aim 1 and 2 in which our
dependent variable (Genotype or Haplotype) was utilized to estimate the probability of a
conditioning the independent disease outcome variable (SMA and RPI<2). To overcome
false discovery or reduced statistical impact, we used two disease categories, SMA and
RPI<2, to indicate the most significant findings. This was important for determining the
impact of genotypes or haplotypes of both immune (MIG and IP-10) and hemoglobin
based (HBA2) genes and influential role in both SMA and erythropoietic response.

There are several pathways yet to be examined more closely within the context of
mediator influence on severe disease. The use of cell models in which gene expression is
measured based on disease category or variation within specific gene regions could prove
useful to determine causality. For example, the use of gene reporter plasmid assays that
are specific for gene regions that vary between genotypes could demonstrate loss of gene
function in vitro. Similar experiments [electrophoretic mobility shift assay (EMSA)]
focusing on transcription factor binding elements and genotype specific regions presented
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in this work could reveal the influence of transcription factors on protein expression.
Currently, we are investigating gene transcripts and pathways using RNA sequencing
data collected from the CD34+ in vitro experiments presented here. The results collected
from these and future studies will be beneficiary in advancing our understanding of the
biomolecular pathways that constitute erythropoietic response in children with SMA.
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